

**CURRICULUM VITAE**  
**Stacie B. Dusetzina, PhD**

**Office Address**

2525 West End Avenue, Suite 1203  
Nashville, TN, 37205  
Phone: 615-875-9281; Email: [s.dusetzina@vanderbilt.edu](mailto:s.dusetzina@vanderbilt.edu)

**Education**

*Research Fellow* 2010 – 2012  
Department of Health Care Policy  
Harvard Medical School

*Pharmaceutical Sciences, PhD* 2006 – 2010  
Eshelman School of Pharmacy, Division of Pharmaceutical Outcomes and Policy  
University of North Carolina at Chapel Hill

*Epidemiology, PhD Minor*  
University of North Carolina at Chapel Hill, Gillings School of Global Public Health

*Psychology, Management & Society, Dual Majors, BA* 1998-2002  
University of North Carolina at Chapel Hill

**Professional Experience**

*Professor of Health Policy* 2022 - Present  
*Ingram Professor of Cancer Research*  
Vanderbilt University School of Medicine, Department of Health Policy

*Associate Professor of Health Policy (Tenured)* 2018 - 2022  
*Ingram Associate Professor of Cancer Research*  
Vanderbilt University School of Medicine, Department of Health Policy

*Assistant Professor Division of Pharmaceutical Outcomes and Policy* 2014 - 2018  
University of North Carolina at Chapel Hill Eshelman School of Pharmacy

*Assistant Professor of Health Policy and Management* 2012 - 2018  
University of North Carolina at Chapel Hill, Gillings School of Global Public Health

*Assistant Professor of General Medicine and Clinical Epidemiology* 2012 - 2014  
University of North Carolina at Chapel Hill School of Medicine

*Associate Member, Lineberger Comprehensive Cancer Center* 2012 - 2018  
University of North Carolina at Chapel Hill

*Fellow, Cecil G. Sheps Center for Health Services Research* 2012 - 2018  
University of North Carolina at Chapel Hill

Clinical Trials Project Manager 2003 - 2006  
Rho, Inc., Contract Research Organization, Chapel Hill, NC

**Key Professional Activities**

- Commissioner, Medicare Payment Advisory Commission (MedPAC) 2021 - Present  
 Expert Witness for Senate Aging Committee Hearing on The Complex Web of Prescription Drug Prices: 2019  
<https://www.aging.senate.gov/hearings/the-complex-web-of-prescription-drug-prices-part-ii-untangling-the-web-and-paths-forward>
- National Academies of Sciences, Engineering and Medicine Committee Member 2016, 2017  
<http://www8.nationalacademies.org/cp/CommitteeView.aspx?key=49817>  
 Study: Ensuring Patient Access to Affordable Drugs
- Invited Participant, President's Cancer Panel Workshop 2016, 2017  
<http://www.aspph.org/unc-faculty-member-invited-to-inform-presidents-cancer-panel-about-cancer-drug-pricing-and-access/>

**Bibliography****Refereed Papers**

(\* = Role as Faculty Mentor; \*\* = Lead Methodologist)

1. Baig K, **Dusetzina SB\***. Premiums and Out-of-Pocket Spending for Long-acting Insulins Under the Medicare Part D Senior Savings Model. *JAMA*. 2022 Nov 11:e2217232. Epub ahead of print. PMID: 36368009; PMCID: PMC9652766.
2. Mattingly TJ, Everson J, Besaw RJ, Whitmore CC, Henderson SC, **Dusetzina SB**. "Worth it if you could afford it": Patient perspectives on integrating real-time benefit tools into drug cost conversations. *J Am Geriatr Soc*. 2023 Jan 13. PMID: 36637794.
3. Johnson M, Nayak RK, Gilstrap L, **Dusetzina SB\***. Estimation of Out-of-Pocket Costs for Guideline-Directed Medical Therapy for Heart Failure Under Medicare Part D and the Inflation Reduction Act. *JAMA Cardiol*. 2023 Jan 11. PMID: 36630145.
4. Essien UR, Lusk JB, **Dusetzina SB**. Cost-Sharing Reform for Chronic Disease Treatments as a Strategy to Improve Health Care Equity and Value in the US. *JAMA Health Forum*. 2022 Dec 2;3(12):e224804. PMID: 36580324.
5. Etteldorf A, Sedhom R, Rotolo SM, Vogel RI, Booth CM, Blaes AH, Virnig BA, **Dusetzina SB**, Gupta A. The least costly pharmacy for cancer supportive care medications over time: the logistic toxicity of playing catch up. *Support Care Cancer*. 2022 Dec 13;31(1):3. PMID: 36512134; PMCID: PMC9745713.
6. Sachs RE, Donohue JM, **Dusetzina SB**. Reforming Reimbursement for the US Food and Drug Administration's Accelerated Approval Program to Support State Medicaid Programs. *JAMA Health Forum*. 2022 Nov 4;3(11):e224115. PMID: 36399351.
7. **Dusetzina SB**, Huskamp HA, Qin X, Keating NL. Prescription Drug Spending in Fee-for-Service Medicare, 2008-2019. *JAMA*. 2022 Oct 18;328(15):1515-1522. PMID: 36255428.
8. **Dusetzina SB**, Huskamp HA. Impending Relief for Medicare Beneficiaries – The Inflation Reduction Act. *N Engl J Med*. 2022 Oct 20;387(16):1437-1439. PMID: 36251774.

9. Joyce DD, Sharma V, Jiang DH, Van Houten HK, Sangaralingham LR, Borah BJ, Kwon ED, Penson DF, **Dusetzina SB**, Tilburt JC, Boorjian SA. Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients. *J Urol*. 2022 Nov;208(5):987-996.
10. Gupta A, Arora N, Haque W, Hussaini SMQ, Sedhom R, Blaes AH, **Dusetzina SB\***. Out-of-pocket costs of oral anticancer drugs for Medicare beneficiaries vary by strength and formulation. *J Geriatr Oncol*. 2022 Oct 10:S1879-4068(22)00235-1. PMID: 36229377.
11. Shafer PR, Horný M, **Dusetzina SB**. Monthly Cost-Sharing Limits and Out-of-pocket Costs for Commercially Insured Patients in the US. *JAMA Netw Open*. 2022 Sep 1;5(9):e2233006. PMID: 36107430; PMCID: PMC9478767.
12. Hwang TJ, Kesselheim AS, **Dusetzina SB**. Reforming Patient Cost Sharing for Cancer Medications in Medicare Part D. *JAMA Oncol*. 2022 Aug 4. Epub ahead of print. PMID: 35925591.
13. Rathi VK, Scangas GA, Metson RB, Xiao R, Nshuti L, **Dusetzina SB\***. Out-of-pocket costs of biologic treatments for chronic rhinosinusitis with nasal polyposis in the Medicare population. *Int Forum Allergy Rhinol*. 2022 Oct;12(10):1295-1298.
14. Everson J, Whitmore C, Mattingly TJ, Sinaiko A, **Dusetzina SB**. Physician Perspectives on Implementation of Real-Time Benefit Tools: A Qualitative Study. *Appl Clin Inform*. 2022 Sep 19.
15. Etteldorf A, Rotolo S, Sedhom R, Vogel RI, Blaes A, **Dusetzina SB**, Virnig B, Gupta A. Finding the Lowest-Cost Pharmacy for Cancer Supportive Care Medications: Not So Easy. *JCO Oncol Pract*. 2022 Aug;18(8):e1342-e1349. PMID: 35623024; PMCID: PMC9377721.
16. Haque W, Chencheri S, Virnig BA, Blaes AH, Booth CM, **Dusetzina SB**, Gupta A. Price Comparison of Human and Veterinary Formulations of Common Medications. *JAMA Intern Med*. 2022 Sep 12. doi: 10.1001/jamainternmed.2022.3938. Epub ahead of print. PMID: 36094526.
17. Gupta A, Antonarakis ES, Blaes AH, Booth CM, **Dusetzina SB**. Evaluation of Medicare Coverage and Estimated Out-of-Pocket Costs for Generic Abiraterone Products. *JAMA Netw Open*. 2022 Sep 1;5(9):e2231475. doi: 10.1001/jamanetworkopen.2022.31475. PMID: 36178694.
18. Hussaini SMQ, Gupta A, **Dusetzina SB**. What Should I Know About Coverage With Medicare Part D? *JAMA Intern Med*. 2022 Sep 1;182(9):1016. doi: 10.1001/jamainternmed.2022.2880. PMID: 35877090.
19. Hussaini SMQ, Sedhom R, **Dusetzina SB**, Gupta A. Intermediate Strengths and Inflated Prices: The Story of Transdermal Fentanyl Patches. *J Palliat Med*. 2022 Sep;25(9):1335-1337. doi: 10.1089/jpm.2022.0241. Epub 2022 Jun 28. PMID: 35763285.
20. Sachs RE, Donohue JM, **Dusetzina SB**. Accelerated Approval - Taking the FDA's Concerns Seriously. *N Engl J Med*. 2022 Jul 21;387(3):199-201. doi: 10.1056/NEJMp2204487. Epub 2022 Jul 6. PMID: 35793197.

21. Sachs RE, Jazowski SA, Gavulic KA, Donohue JM, **Dusetzina SB**. Medicaid and Accelerated Approval: Spending on Drugs with and without Proven Clinical Benefits. *J Health Polit Policy Law*. 2022 Jul 14:10041107. doi: 10.1215/03616878-10041107. Epub ahead of print. PMID: 35867545.
22. **Dusetzina SB**. Your Money or Your Life - The High Cost of Cancer Drugs under Medicare Part D. *N Engl J Med*. 2022 Jun 9;386(23):2164-2167. Epub 2022 May 4. PMID: 35507526.
23. **Dusetzina SB**, Huskamp HA, Rothman RL, Pinheiro LC, Roberts AW, Shah ND, Walunas TL, Wood WA, Zuckerman AD, Zullig LL, Keating NL. Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions. *Health Affairs*. 2022 April 4.
24. Everson J, Henderson SC, Cheng A, Senft N, Whitmore C, **Dusetzina SB**. Demand for and Occurrence of Medication Cost Conversations: A Narrative Review. *Med Care Res Rev*. 2022 Jul 8:10775587221108042. doi: 10.1177/10775587221108042. Epub ahead of print. PMID: 35808853.
25. Hussaini SMQ, Gupta A, **Dusetzina SB\***. Financial Toxicity of Cancer Treatment. *JAMA Oncol*. 2022 May 1;8(5):788. PMID: 35266966.
26. Chino F, Carroll A, Sanger-Katz M, **Dusetzina SB**, Zafar SY. Communicating Research to Non-Researcher Audiences: A Panel Discussion From the National Cancer Institute's Future of Cancer Health Economics Research Conference. *J Natl Cancer Inst Monogr*. 2022 Jul 5;2022(59):64-67. doi: 10.1093/jncimonographs/lgab021. PMID: 35788377; PMCID: PMC9255936.
27. Das RK, **Dusetzina SB\***. Gender-Affirming Hormone Therapy Spending and Use in the USA, 2013-2019. *J Gen Intern Med*. 2022 Jun 13. doi: 10.1007/s11606-022-07693-0. Epub ahead of print. PMID: 35697969.
28. Kyle MA, **Dusetzina SB**, Keating NL. Evaluation of Trends in Oncology Drug Spending in Medicare, 2016 to 2020. *JAMA Netw Open*. 2022 Jul 1;5(7):e2221468. doi: 10.1001/jamanetworkopen.2022.21468. PMID: 35816318; PMCID: PMC9280395.
29. Shen X, Spratt DE, **Dusetzina SB**, Chen RC. Variations in Medical Necessity Determinations Across Commercial Insurance Carriers for Prostate Cancer Procedures. *Int J Radiat Oncol Biol Phys*. 2022 Jul 30:S0360-3016(22)02597-4. doi: 10.1016/j.ijrobp.2022.07.1839. Epub ahead of print. PMID: 35918053.
30. **Dusetzina SB**. Relief in Sight — Estimated Savings Under Medicare Part D Redesign. *New England Journal of Medicine*. 2021 Nov 10. PMID: 34758246
31. **Dusetzina SB**, Sarpatwari A, Carrier MA, Hansen RA, Keating NL, Huskamp HA. Patient and Payer Incentives to Use On-Patent Brand-Name Drugs Over Authorized Generics in Medicare Part D. *JAMA Internal Medicine*. 2021 Oct 18:e215997. PMID: 34661600
32. Essien UR, **Dusetzina SB**, Gellad WF. A Policy Prescription for Reducing Health Disparities-Achieving Pharmaco-equity. *JAMA*. 2021 Nov 9;326(18):1793-1794. PMID: 34677579.

33. Horný M, Shafer PR, **Dusetzina SB**. Concordance of Disclosed Hospital Prices With Total Reimbursements for Hospital-Based Care Among Commercially Insured Patients in the US. *JAMA Netw Open*. 2021 Dec 1;4(12):e2137390. PMID: PMC8669520.
34. Xiao R, Ross JS, Gross CP, **Dusetzina SB**, McWilliams JM, Sethi RKV, Rathi VK. Hospital-Administered Cancer Therapy Prices for Patients With Private Health Insurance. *JAMA Intern Med*. 2022 Jun 1;182(6):603-611. PMID: 35435948; PMID: PMC9016607.
35. Sachs RE, Gavulic KA, Donohue JM, **Dusetzina SB**. Changes in the Use of Hydroxyprogesterone Caproate Injection After Confirmatory Trial Failure. *JAMA Intern Med*. 2021 Dec 6:e217001. PMID: PMC8649909.
36. Hwang TJ, Qin X, Keating NL, Huskamp HA, **Dusetzina SB\***. Assessment of Out-of-Pocket Costs with Rebate Pass-Through for Brand-Name Cancer Drugs Under Medicare Part D. *JAMA Oncology*. 2021 Nov 11:e215433. PMID: 34762097
37. Etteldorf A, Rotolo S, Sedhom R, Vogel RI, Blaes A, **Dusetzina SB**, Virnig B, Gupta A. Finding the Lowest-Cost Pharmacy for Cancer Supportive Care Medications: Not So Easy. *JCO Oncol Pract*. 2022 May 27:OP2200051. PMID: 35623024.
38. Das RK, **Dusetzina SB\***. Gender-Affirming Hormone Therapy Spending and Use in the USA, 2013-2019. *J Gen Intern Med*. 2022 Jun 13. PMID: 35697969.
39. Rathi VK, Scangas GA, Metson RB, Xiao R, Nshuti L, **Dusetzina SB**. Out-of-pocket costs of biologic treatments for chronic rhinosinusitis with nasal polyposis in the Medicare population. *Int Forum Allergy Rhinol*. 2022 Jan 14. PMID: 35029845.
40. Jazowski SA, Wilson L, **Dusetzina SB\***, Zafar SY, Zullig LL. Association of High-Deductible Health Plan Enrollment With Spending on and Use of Lenalidomide Therapy Among Commercially Insured Patients With Multiple Myeloma. *JAMA Netw Open*. 2022 Jun 1;5(6):e2215720. PMID: 35671056; PMID: PMC9175078.
41. Sachs RE, Gavulic KA, Donohue JM, **Dusetzina SB**. Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval. *JAMA Health Forum*. 2021 Oct 8;2(10):e213177. doi: 10.1001/jamahealthforum.2021.3177. PMID: 35977163; PMID: PMC8727037.
42. Desai N, Besaw RJ, Sedhom R, Qasim Hussaini SM, Blaes AH, **Dusetzina SB**, Gupta A. Estimated out-of-pocket costs for cancer-directed and supportive care medications for older adults with advanced pancreatic cancer. *J Geriatr Oncol*. 2022 Jun;13(5):754-757. PMID: 35168921.
43. Lai LY, Oerline MK, Kaufman SR, Herrel LA, Skolarus TA, **Dusetzina SB**, Ellimoottil C, Shahinian VB, Hollenbeck BK, Caram MEV. Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide. *Urology*. 2021 Dec 1:S0090-4295(21)01103-1. PMID: 34861316.

44. Yeung K, **Dusetzina SB**, Basu A. Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018. *JAMA Network Open*. 2021 Jun 1;4(6):e2113393. PMID: 34125219
45. **Dusetzina SB**, Huskamp HA, Jazowski SA, Winn AN, Basch E, Keating NL. Comparison of Anticancer Medication Use and Spending Under United States Oncology Parity Laws With and Without Out-of-Pocket Spending Caps. *JAMA Health Forum*. (In Press)
46. Pourali SP, Nshuti L, **Dusetzina SB\***. Out-of-Pocket Costs of Specialty Medications for Psoriasis and Psoriatic Arthritis Treatment in the Medicare Population. *JAMA Dermatol*. 2021 Oct 1;157(10):1239-1241. PMID: 34524386; PMCID: PMC8444058.
47. **Dusetzina SB**, Elkins W, Hoadley J. Extra Help Needs a Hand: Partial Subsidies in Medicare Part D Program. *Journal of General Internal Medicine*. 2021 May 23. PMID: 34027607
48. Wallis CJD, Joyce DD, Klaassen Z, Luckenbaugh AN, Laviana AA, Penson D, **Dusetzina SB**, Barocas DA. Out-of-pocket costs for commercially insured patients with localized prostate cancer. *Urol Oncol*. 2021 Dec;39(12):797-805. PMID: 34600803.
49. Gupta A, Nshuti L, Grewal US, Sedhom R, Check DK, Parsons HM, Blaes AH, Virnig BA, Lustberg MB, Subbiah IM, Nipp RD, Dy SM, **Dusetzina SB\***. Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms. *JCO Oncol Pract*. 2021 Sep 24:OP2100466. PMID: 34558297.
50. Gupta A, Premnath N, Sedhom R, Beg MS, Khera R, Laheru DA, **Dusetzina SB\***. Projected 30- day out-of-pocket costs and total spending on pancreatic enzyme replacement therapy under Medicare Part D. *Pancreatology*. 2021 Aug 21; (5): 1009-1010. PMID:34006458.
51. Mitchell AP, Mishra A, Dey P, Curry MA, Trivedi NU, Haddadin M, Rahman MW, Winn AN, **Dusetzina SB**, Bach PB. Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines. *Oncologist*. 2021 May 13. PMID:33982829.
52. Auty SG, Shafer PR, **Dusetzina SB**, Griffith KN. Association of Medicaid Managed Care Drug Carve Outs With Hepatitis C Virus Prescription Use. *JAMA Health Forum*. (In Press)
53. Yachimski PS, Lucas A, **Dusetzina SB**. Trends in performance of ERCP among patients with surgically unresectable pancreatic cancer: a SEER-Medicare database study. *Gastrointestinal Endoscopy*. 2021 Oct;94(4):752-759.e1. PMID: 33862104.
54. Samuel-Ryals, CA, Mbah, OM, Peacock-Hinton, S, Cross, SH, Reeve, BB, **Dusetzina, SB**. Evaluating the Contribution of Patient-Provider Communication and Cancer Diagnosis to Racial Disparities in End-of-Life Care among Medicare Beneficiaries. *Journal of General Internal Medicine*. 2021 Nov;36(11):3311-3320. PMID: 33963508
55. **Dusetzina SB**, Keating NL, Huskamp HA. Authorized Generics and Their Evolving Role in Prescription Drug Pricing and Access. *JAMA Internal Medicine*. 2021 Jan 25. PMID:33492347

56. **Dusetzina SB**, Cubanski J, Roberts D, Hoadley J, True S, Nshuti L, Neuman T. Trends in Medicare Part D Coverage of Generics with Equivalent Brands. *American Journal of Managed Care*. 2021 Jul;27(7):283-288. PMID: 34314117
57. **Dusetzina SB**, Muluneh B, Keating NL, Huskamp HA. Broken Promises - How Medicare Part D Has Failed to Deliver Savings to Older Adults. *New England Journal of Medicine*. 2020 Dec 10;383(24):2299-2301. PMID: 33283988
58. Chen S, Krishnan S, Shafer PR, **Dusetzina SB**, Horný H. Annual Out-Of-Pocket Spending Clusters Within Short Time Intervals: Implications For Health Care Affordability. *Health Affairs*. 2021 Feb. 40; 274-280.
59. Sachs RE, Donohue JM, **Dusetzina SB**. Confronting State Medicaid Drug Spending Pressures. *JAMA*. 2020 Oct 9. PMID: 33034613
60. Yeung K, Barthold D, **Dusetzina SB**, Basu A. Patient and Plan Spending after State Specialty-Drug Out-of-Pocket Spending Caps. *New England Journal of Medicine*. 2020 Aug 6; 383(6):558-566. PMID:32757524.
61. Everson J, Cheng AK, Patrick SW, **Dusetzina SB**. Association of Electronic Prescribing of Controlled Substances With Opioid Prescribing Rates. *JAMA Netw Open*. 2020 Dec 1;3(12):e2027951. PMID: 33346845
62. Gavulic KA, **Dusetzina SB\***. Prescription Drug Priorities under the Biden Administration. *J Health Polit Policy Law*. 2021 Jan 22:8970810. PMID: 33503239
63. Hollenbeck BK, Oerline M, Kaufman SR, Caram MEV, **Dusetzina SB**, Ryan AM, Shahinian VB. Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies. *Urology*. 2020 Oct 16:S0090-4295(20)31260-7. PMID: 33075381
64. Caram MEV, Oerline MK, **Dusetzina SB**, Herrel LA, Modi PK, Kaufman SR, Skolarus TA, Hollenbeck BK, Shahinian V. Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer. *Cancer*. 2020 Dec 1; 126(23):5050-5059. PMID:32926427
65. **Dusetzina SB**, Cubanski J, Nshuti L, True S, Hoadley J, Roberts D, Neuman T. Medicare Part D Plans Rarely Cover Brand-Name Drugs When Generics Are Available. *Health Affairs*. 2020 Aug; 39(8):1326-1333. PMID:32744944.
66. Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, **Dusetzina SB**, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Lyman GH. Antiemetics: ASCO Guidelien Update. *J Clin Oncol*. 2020 Aug 20;38(24):2782-2797. PMID:32641378.
67. Gokhale M, **Dusetzina SB**, Pate V, Chun DS, Buse JB, Stürmer T, Gower EW. Decreased Antihyperglycemic Drug Use Driven by High Out-of-Pocket Costs Despite Medicare Coverage Gap Closure. *Diabetes Care*. 2020 Sep;43(9):2121-2127. PMID:32641378.

68. Shafer PR, **Dusetzina SB**, Sabik LM, Platts-Mills TF, Stearns SC, Trogdon JG. Insurance instability and use of emergency and office-based care after gaining coverage: An observational cohort study. *PLoS One*. 2020 Sep 4;15(9):e0238100. eCollection 2020. PMID: 32886675
69. Agarwal A, Roberts A, **Dusetzina SB**, Royce TJ. Changes in Opioid Prescribing Patterns Among Generalists and Oncologists for Medicare Part D Beneficiaries From 2013 to 2017. *JAMA Oncology*. 2020 May 29;6(8):1-4. PMID:32469405.
70. Jazowski SA, **Dusetzina SB**. Addressing cost-related nonadherence to oral anticancer medications through health policy reform: Challenges and opportunities. *Cancer*. 2020 Aug 15; 126(16):3613-3616. PMID:32438468.
71. Savitz ST, Bailey SC, Dusetzina SB, Jones WS, Trogdon JG, Stearns SC. Treatment selection and medication adherence for stable angina: The role of area-based health literacy. *J Eval Clin Pract*. 2020 Dec;26(6):1711-1721. PMID: 31994280
72. Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, **Dusetzina SB**, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Lyman GH. Antiemetics: ASCO Guideline Update. *J Clin Oncol*. 2020 Aug 20;38(24):2782-2797. PMID: 32658626
73. Roberts AW, Eiffert S, Wulff-Burchfield EM, **Dusetzina SB**, Check DK. Opioid use disorder and overdose in older adults with breast, colorectal, or prostate cancer. *J Natl Cancer Inst*. 2020 Aug 17:djaa122. PMID: 32805032
74. Erath A, **Dusetzina SB\***. Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019. *JAMA Network Open*. 2020 Apr 1;3(4). PMID:32338754.
75. **Dusetzina SB**, Huskamp HA, Keohane LM, Keating NL. Medicare Part D and Insulin Affordability-The Devil Is in the Details. *New England Journal of Medicine*. 2020 May 14;382(20):1878-1880. PMID:32237673.
76. Leech AA, Neumann PJ, Cohen JT, Jagasia M, **Dusetzina SB**. Balancing Value with Affordability: Cell Immunotherapy for Cancer Treatment in the US. *The Oncologist*. 2020 Jul;25(7):e1117-e1119. PMID:32386072.
77. Dong OM, Wheeler SB, Cruden G, Lee CR, Voora D, **Dusetzina SB**, Wiltshire T. Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. *Value Health*. 2020 Jan;23(1):61-73. PMID: 31952675
78. Hollenbeck BK, Oerline M, Kaufman SR, Caram MEV, **Dusetzina SB**, Ryan AM, Shahinian VB. Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies. *Urology*. 2020 Oct 16:S0090-4295(20)31260-7. PMID: 33075381
79. Cole AL, Wood WA, Muluneh B, Lund JL, Elston Lafata J, **Dusetzina SB\***. Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib. *Journal of Oncology Practice*. 2020 May; 16(5):e443-3445. PMID:32196424.



80. Conti R, **Dusetzina SB**, Sachs R. How The ACA Reframed The Prescription Drug Market And Set The Stage For Current Reform Efforts: A look back at the ACA's successes and missed opportunities at improving prescription drug affordability. *Health Affairs*. 2020.
81. Ramsey SD, **Dusetzina SB**. Weighing Costs and Benefits in the Economics of Cancer Care. *J Clin Oncol*. 2020 Feb 1;38(4):289-291. PMID: 31804863
82. Nguyen JT, Cole AL, Leech AA, Wood WA, **Dusetzina SB\***. Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia. *Value Health*. 2020 Oct;23(10):1292-1299. PMID: 33032772
83. Gavulic KA, Pelletier-Fleury N, **Dusetzina SB\***. Peer Comparisons for Drug Price Setting: Why International Reference Pricing May Not Provide Optimal Prices. *JAMA Health Forum*. 2020.
84. **Dusetzina SB**, Oberlander J. Advancing Legislation on Drug Pricing - Is There a Path Forward? *New England Journal of Medicine*. 2019 Nov 28;381(22):2081-2084. PMID: 31774951
85. Everson J, Frisse M, **Dusetzina SB**. Real-Time Benefit Tools for Drug Prices. *JAMA*. 2019;322(24):2383-2384. PMID: 31651954
86. Chou YT, Farley JF, Stinchcombe TE, Proctor AE, Lafata JE, **Dusetzina SB\***. The Association Between Medicare Low-income Subsidy and Anticancer Treatment Uptake in Advanced Lung Cancer. *Journal of the National Cancer Institute*. 2020 Jun 1; 112(6):637-646. PMID: 31501872
87. Cole AL, Jazowski SA, **Dusetzina SB\***. Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia. *Pharmacoepidemiology and Drug Safety*. 2019 Sep 11. PMID: 31507005
88. **Dusetzina SB**, Keating NL, Huskamp HA. Proposals to Redesign Medicare Part D -- Easing the Burden of Rising Drug Prices. *New England Journal of Medicine*. 2019 Oct 10;381(15):1401-1404. PMID:31483987
89. **Dusetzina SB**, Huskamp HA, Jazowski SA, Winn AN, Wood WA, Olszewski A, Basch E, Keating NL. Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients with Blood Cancer. *J Natl Cancer Inst*. 2020 Oct 1; 112(10):1055-1062. PMID: 31883008
90. Mitchell AP, Kinlaw AC, Peacock-Hinton S, **Dusetzina SB**, Sanoff HK, Lund JL. Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice. *Oncologist*. 2020 Jan;25(1):46-54. PMID: 31611329
91. Ernecoff NC, Wessell KL, Hanson LC, **Dusetzina SB**, Shea CM, Weinberger M, Bennett AV. Elements of Palliative Care in the Last 6 Months of Life: Frequency, Predictors, and Timing. *J Gen Intern Med*. 2020 Mar; 35(3):753-761. PMID: 31650402.
92. Ernecoff NC, Wessell KL, Hanson LC, Shea CM, **Dusetzina SB**, Weinberger M, Bennett AV. Does receipt of recommended elements of palliative care precede in-hospital death or hospice referral? *J Pain Symptom Manage* 2020 Apr; 59(4):778-786. PMID: 31836536

93. Henderson SC, Owino H, Thomas KC, Cyr JM, Ansari S, Glickman SW, **Dusetzina SB\***. Post-discharge Health Services Use for Patients with Serious Mental Illness Treated at an Emergency Department Versus a Dedicated Community Mental Health Center. *Adm Policy Ment Health*. 2020 May; 47(3):443-450. PMID: 31813067
94. Wang LK, Quach HT, Moodabigil NV, Davis EJ, Sosman JA, **Dusetzina SB**, Johnson DB. Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors. *Cancer*. 2020 Jan 15;126(2):322-328. PMID: 31580492
95. **Dusetzina SB**, Huskamp HA, Keating NL. Specialty Drug Pricing and Out-of-Pocket Spending on Orally-Administered Anticancer Drugs in Medicare Part D, 2010 to 2019. *JAMA*. 2019. 321(30).
96. **Dusetzina SB**, Bach PB. Prescription Drugs-List Price, Net Price, and the Rebate Caught in the Middle. *JAMA*. 2019 Mar 6. PMID: 30840047.
97. Hwang TJ, **Dusetzina SB**, Feng J, Maini L, Kesselheim AS. Price Increases of Protected-Class Drugs in Medicare Part D, Relative to Inflation, 2012-2017. *JAMA*. 2019 July 16; 322(3):267-269. PMID:31310287.
98. Ernecoff NC, Wessell KL, Hanson LC, Lee AM, Shea CM, **Dusetzina SB**, Weinberger M, Bennett AV. Electronic Health Record Phenotypes for Identifying Patients with Late-Stage Disease: a Method for Research and Clinical Application. *J Gen Intern Med*. 2019. August 8.
99. Savitz ST, Dobler CC, Shah ND, Bennett AV, Bailey SC, **Dusetzina SB**, Jones WS, Stearns SC, Montori VM. Patient-Clinician Decision Making for Stable Angina: The Role of Health Literacy. *EGEMS*. 2019. August 9.
100. Bushnell GA, Gaynes BN, Compton SN, Dusetzina SB, Olfson M, Sturmer T. Incident Substance Use Disorder Following Anxiety Disorder in Privately Insured Youth. *J Adolesc Health*. 2019 July 17.
101. Mahendraratnam N, Farley JF, Basch E, Proctor A, Wheeler SB, **Dusetzina SB\***. Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy. *Supportive Care Cancer*. 2019 Mar 26. PMID: 30915567
102. Mitchell AP, Winn AN, Lund JL, **Dusetzina SB\***. Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology. *Oncologist*. 2019 Feb 9. PMID: 30728276.
103. Pace LE, **Dusetzina SB**, Horowitz ME, Keating NL. Utilization of Long-Acting Reversible Contraceptives in the United States After vs Before the 2016 US Presidential Election. *JAMA Internal Medicine*. 2019 Feb 4. PMID: 30715075
104. **Dusetzina SB**, Mello MM. Disclosing Prescription-Drug Prices in Advertisements — Legal and Public Health Issues. *New England Journal of Medicine*. 2018 Nov 14.
105. Ellis CT, Cole AL, Sanoff HK, Hinton S, **Dusetzina SB**, Stitzenberg KB. Evaluating Surveillance Patterns after Chemoradiation-Only Compared with Conventional Management for Older Patients with Rectal Cancer. *J Am Coll Surg*. 2018 Jan 25. PMID 30685478

106. Knight TG, Deal AM, **Dusetzina SB**, Muss HB, Choi SK, Bensen JT, Williams GR. Financial Toxicity in Adults with Cancer: Adverse Outcomes and Noncompliance. *Journal of Oncology Practice*. 2018 Oct 24. PMID:30355027
107. Olszewski AJ, **Dusetzina SB**, Trivedi AN, Davidoff AJ. Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries. *Journal of Clinical Oncology*. 2018 Aug 16. PMID:30113885
108. Pinheiro L, Check DK, Rosenstein DL, Reeder-Hayes KE, **Dusetzina SB\***. Examining Potential Gaps in Supportive Medication Use for U.S. and Foreign Born Hispanic Women with Breast Cancer. *Supportive Care in Cancer*. 2018 Aug 10. PMID:30097792
109. Bushnell GA, Gaynes BN, Compton SN, **Dusetzina SB**, Brookhart MA, Sturmer T. Incidence of mental health hospitalizations, treated self-harm, and emergency room visits following new anxiety disorder diagnoses in privately insured U.S. children. *Depression and Anxiety*. 2018 Oct 24. PMID:30358025
110. Check DK, Kwan ML, Chawla N, **Dusetzina SB**, Valice E, Ergas IJ, Roh JM, Kolevska T, Rosenstein DL, Kushi LH. Opportunities to Improve Detection and Treatment of Depression among Patients with Breast Cancer Treated in an Integrated Delivery System. *J Pain Symptom Manage*. 2018 Nov 30. PMID:30508637
111. Bushnell GA, **Dusetzina SB**, Compton SN, Gaynes BN, Brookhart MA, Sturmer T. Psychotherapy Claims Surrounding Pharmacotherapy Initiation in Children and Adolescents with Anxiety Disorders. *Journal of Child and Adolescent Psychopharmacology*. 2018 Dec 19. PMID: 30565956.
112. Hickson RP, Cole AL, **Dusetzina SB\***. Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes. *Journal of Managed Care Specialty Pharmacy*. 2019 Jan; 25(1):72-79. PMID: 30589625.
113. Belenky N, Pence BW, Cole SR, **Dusetzina SB**, Edmonds A, Oberlander J, Plankey M, Adedimeji A, Wilson TE, Cohen J, Cohen MH, Milam JE, Adimora AA. Impact of Medicare Part D on mental health treatment and outcomes for dual eligible beneficiaries with HIV. *AIDS Care*. 2018 Sep 6:1-8. PMID:30189747
114. Wright B, **Dusetzina SB**, Upchurch G. Medicare's Variation in Out-of-Pocket Costs for Prescriptions: The Irrational Examples of In-Hospital Observation and Home Infusion. *Journal of the American Geriatrics Society*. 2018 Sep 28. PMID:30264858
115. Hickson R, Cole AL, **Dusetzina SB\***. Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes. *Journal of Managed Care and Specialty Pharmacy*.
116. Cole AL, **Dusetzina SB\***. Generic Price Competition for Specialty Drugs: Too Little, Too Late? *Health Affairs*. Health Aff (Millwood). 2018 May; 37(5):738-742. PMID: 29733710

117. Roberts AW, Saloner B, **Dusetzina SB\***. Buprenorphine Use and Spending for Opioid Use Disorder Treatment: Trends from 2003 to 2015. *Psychiatric Services*. 2018 May 8. PMID: 29734918
118. Mitchell A, Winn AN, **Dusetzina SB\***. Pharmaceutical Industry Payments and Oncologists' Selection of Targeted Cancer Therapies in Medicare Beneficiaries. *JAMA Internal Medicine*. 2018 Jun 1; 178(6):854-856. PMID: 29630687
119. **Dusetzina SB**, Cubanski J, Rowland D, Ramsey S. Improving Affordability of Specialty Drugs by Addressing Patient Out-of-Pocket Spending. *Health Affairs Prescription Drug Pricing*.
120. Spencer JC, Brewer NT, Trogdon JG, Wheeler SB, **Dusetzina SB\***. Predictors of Human Papillomavirus Vaccine Follow-Through Among Privately Insured US Patients. *American Journal of Public Health*. 2018 Jul; 108(7):946-950. PMID: 29771616
121. Bushnell GA, Brookhart MA, Gaynes BN, Compton SN, **Dusetzina SB**, Stürmer T. Examining parental medication adherence as a predictor of child medication adherence in pediatric anxiety disorders. *Medical Care*. 2018 Jun; 56(6):510-519. PMID: 29668649
122. **Dusetzina SB**, Huskamp HA, Winn AN, Basch EM, Keating NL. Changes in Out-of-Pocket and Health Care Spending for Patients Using Orally-Administered Anticancer Therapy Following State Parity Law Adoption. *JAMA Oncology*. 2017 Nov 9. PMID:29121177
123. Winn AN, Keating NL, Trogdon J, Basch E, **Dusetzina SB\***. Spending by Commercial Insurers on Chemotherapy Based on Site of Care, 2004-2014. *JAMA Oncology*. 2018 Apr 1; 4(4):580-581. PMID: 29470578
124. Belenky N, Pence BW, Cole SR, **Dusetzina SB**, Edmonds A, Oberlander J, Plankey MW, Adedimeji A, Wilson TE, Cohen J, Cohen MH, Milam JE, Golub ET, Adimora AA. Associations between Medicare Part D and Out-of-Pocket Spending, HIV Viral Load, Adherence, and ADAP Use in Dual Eligibles with HIV. *Medical Care*. 2018 Jan; 56(1):47-53. PMID:29227443
125. Cole AL, Sanoff HK, **Dusetzina SB\***. Possible Insufficiency of Generic Price Competition to Contain Prices for Orally Administered Anticancer Therapies. *JAMA Internal Medicine*. 2017 Nov 1; 177(11):1679-1680. PMID:28892541
126. **Dusetzina SB**, Conti RM, Yu N, Bach PB. Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending. *JAMA Internal Medicine*. 2017 Aug 1; 177(8): 1185-1188. PMID: 28558108
127. Rotenstein L, **Dusetzina SB**, Keating NL. Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit. *Journal of Managed Care and Specialty Pharmacy*. J Manag Care Spec Pharm. 2018 Jun; 24(6):494-502. PMID: 29799324
128. Anderson C, Winn AN, **Dusetzina SB**, Nichols H. Endocrine therapy initiation among older women with ductal carcinoma in situ. *Journal of Cancer Epidemiology*. 2017; 2017:6091709. PMID:29056966

129. Smitherman AB, Mohabir D, Wilkins TM, Blatt J, Nichols HB, **Dusetzina SB\***. Early Post-therapy Prescription Drug Usage among Childhood and Adolescent Cancer Survivors. *The Journal of Pediatrics*. 2018 Apr; 195:161-168. PMID: 29395178
130. Durham T, Hassmiller Lich K, Viera AJ, Fine JP, Mukherjee J, Weinberger MW, **Dusetzina SB**. Utilization of Standard and Target-Specific Oral Anticoagulants Among Adults in the United Kingdom With Incident Atrial Fibrillation. *American Journal of Cardiology*. 2017 Nov 15; 120(10):1820-1829. PMID:28867127
131. Olszewski A, **Dusetzina SB**, Davidoff A, Trivedi A. Subsidies for oral chemotherapy and use of immunomodulatory drugs among Medicare beneficiaries with myeloma. *Journal of Clinical Oncology*. 2017 Oct 10; 35(29):3306-3314. PMID:28541791
132. Reeder-Hayes K, Meyer AM, Hinton SP, Meng K, Carey LA, **Dusetzina SB**. Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women with Early Stage Breast Cancer. *Journal of Clinical Oncology* . 2017 Oct 10; 35(29):3298-3305. PMID:28727517
133. Shapiro CL, Moriarty JP, **Dusetzina SB**, Himelstein AL, Foster JC, Grubbs SS, Novotny PJ, Borah BJ. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance). *Journal of Clinical Oncology*. 2017 Oct 12. PMID:29023215
134. Hesketh PJ, Kris MG, Basch EM, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, **Dusetzina SB**, Eng C, Feyer PC, Jordan K, Noonan K, Somerfield MR, Sparacio D, Lyman GH. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. *Journal of Clinical Oncology* . 2017 Oct 1; 35(28):3240-3261. PMID:28759346
135. Bushnell GA, Compton SN, **Dusetzina SB**, Gaynes BN, Brookhart MA, Walkup JT, Rynn MA, Sturmer T. Treating pediatric anxiety: Initial use of SSRIs and other anti-anxiety prescription medications. *Journal of Clinical Psychiatry*. 2017 Oct 31. PMID:29099547
136. Barber EL, **Dusetzina SB\*\***, Stitzenberg KB, Rossi EC, Gehrig PA, Boggess JF, Garrett JM. Variation in Neoadjuvant Chemotherapy Utilization for Epithelial Ovarian Cancer at High Volume Hospitals in the United States and Associated Survival. *Gynecologic Oncology*. 2017 Mar 30. PMID: 28366455
137. Falchook AD, **Dusetzina SB**, Tian F, Basak R, Selvam N, Chen RC. Aggressive end-of-life care for metastatic cancer patients younger than Age 65 Years. *Journal of the National Cancer Institute*. 2017 Sep 1; 109(9). PMID:28954284
138. Roberts M, **Dusetzina SB\***. The Effect of a Celebrity Health Disclosure on Demand for Health Care: Trends in BRCA Testing and Subsequent Health Services Use. *Journal of Community Genetics*. 2017 Apr; 8(2):141-146. PMID: 28299592
139. Chou YT, Winn AN, Rosenstein DL, **Dusetzina SB.\*** Assessing Disruptions in Adherence to Antidepressant Treatments after Breast Cancer Diagnosis. *Pharmacoepidemiology and Drug Safety*. 2017 Mar 19. PMID: 28317314

140. Mahendraratnam N, **Dusetzina SB**, Farley JF. Prescription Drug Utilization and Reimbursement Increased Following State Medicaid Expansion in 2014. *Journal of Managed Care Pharmacy*. 2017 Mar; 23(3):355-363. PMID: 28230452
141. Ellis CT, **Dusetzina SB\*\***, Sanoff HK, Stitzenberg KB. Long-term Survival After Chemoradiotherapy Without Surgery for Rectal Adenocarcinoma: A Word of Caution. *JAMA Oncology*. 2017 Jan 1; 3(1): 123-125. PMID: 27768159.
142. Mitchell AP, Basch EM, **Dusetzina SB\*** Financial relationships with industry among National Comprehensive Cancer Network guideline authors. *JAMA Oncology*. 2016 Dec 1; 2(12): 1628-1631. PMID: 27561170.
143. Adamson A, **Dusetzina SB**. Characteristics of Medicare Payments to Dermatologists in 2013. *JAMA Dermatology*. 2016 Nov 16. PMID: 27851841
144. Winn A, Keating NL, **Dusetzina SB\*** Factors Associated with Tyrosine Kinase Inhibitors Initiation and Adherence among Medicare Beneficiaries with Chronic Myeloid Leukemia. *Journal of Clinical Oncology* . 2016 Dec 20; 34(36): 4323-4328. PMID: 27998234.
145. Pace LE, **Dusetzina SB\*\***, Keating NL. Early impact of the Affordable Care Act on oral contraceptive cost-sharing, adherence, and discontinuation. *Health Affairs*. 2016 Sep 1; 151(9):876-7. PMID: 27168235.
146. Pace LE, **Dusetzina SB\*\***, Keating NL. Early impact of the Affordable Care Act on uptake of long-acting reversible contraceptive methods. *Medical Care*. 2016 Sep; 54(9):811-7. PMID: 27213549.
147. Check DK, Reeder-Hayes KE, Zullig LL, Weinberger M, Basch EM, **Dusetzina SB\***. Examining Racial Variation in Antiemetic Use and Post-Chemotherapy Health Care Utilization for Nausea and Vomiting Among Breast Cancer Patients. *Supportive Care in Cancer*. 2016 Dec; 24(12):4839-4847. PMID:27465051
148. **Dusetzina SB**. Share Of Specialty Drugs In Commercial Plans Nearly Quadrupled, 2003–14. *Health Affairs*. 2016 Jul 07.
149. Doll KM, **Dusetzina SB\*\***, Robinson W. Trends in Inpatient and Outpatient Hysterectomy and Oophorectomy Rates Among Commercially Insured Women in the United States, 2000 – 2014. *JAMA Surgery*. May 2016. PMID: 27168235.
150. Kilfoyle KA, Rahangdale L, **Dusetzina SB\***. Low uptake of human papillomavirus vaccine among postpartum women, 2006 – 2012. *Journal of Women’s Health*. 2016 Jul 22. PMID: 27447054.
151. **Dusetzina SB**. Drug pricing trends for orally-administered anticancer medications reimbursed by commercial health plans 2000-2014. *JAMA Oncology*. 2016 Apr 28.
152. Check DK, Samuel C, Rosenstein DL, **Dusetzina SB\***. Investigation of Racial Disparities in Early Supportive Medication Use and End-of-Life Care among Medicare Beneficiaries with Stage IV Breast Cancer. *Journal of Clinical Oncology*. May 2016. PMID: 27161968.

153. Pergolotti M, Lavery J, Reeve B, **Dusetzina SB\***. The Cost of Disability: The Patient's Financial Burden of Outpatient Occupational and Physical Therapy (**In Press**).
154. Check DK, Rosenstein DL, **Dusetzina SB\***. Early Supportive Medication Use and End-of-life Care among Medicare Beneficiaries with Advanced Breast Cancer. *Supportive Care in Cancer*. 2016. Mar 19. PMID: 26994634.
155. Winn AN, **Dusetzina SB\***. The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer. *Pharmacoepidemiology and Drug Safety*. Apr 2016. PMID:27125337.
156. Check DK, Reeder-Hayes KE, Basch EM, Zullig LL, Weinberger M, **Dusetzina SB\***. Investigating Racial Disparities in Use of NK1 Receptor Antagonists to Prevent Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer. *Breast Cancer Research and Treatment*. 2016. Mar 11. PMID: 26968396.
157. Check DK, Reeder-Hayes KE, Basch EM, Zullig LL, Weinberger M, **Dusetzina SB\***. Investigating Racial Disparities in Use of NK1 Receptor Antagonists to Prevent Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer. *Breast Cancer Research and Treatment*. 2016. Mar 11. PMID: 26968396.
158. Roberts MC, Bryson A, Weinberger M, **Dusetzina SB**, Dinan MA, Reeder-Hayes K, Wheeler SB. Oncologists' Barriers and Facilitators for Oncotype DX Use: Qualitative Study. *International Journal of Technology Assessment in Health Care (In Press)*.
159. Reeder-Hayes K, Hinton SP, Meng K, Carey L, **Dusetzina SB\***. Racial Disparities in Use of HER2-Targeted Therapy for Early Stage Breast Cancer. *Journal of Clinical Oncology*. 2016 April 11. PMID: 27069085.
160. Sanoff HK, Chank YK, Lund JL, O'Neil BH, **Dusetzina SB\***. Sorafenib Effectiveness in Advanced HCC. *The Oncologist*. May 2016. PMID: 27185615.
161. Roberts, MC, Bryson A, Weinberger M, **Dusetzina SB**, Dinan MA, Reeder-Hayes K, Wheeler SB. Patient-Centered Communication for Discussing Oncotype DX Testing. *Cancer Investigation*. Apr 2015. PMID: 27124287.
162. Wang CC, Lu HT, **Dusetzina SB**, Wu CH. The Association between Long-term Bisphosphonate Use and the Risk of Fracture among Women Aged 50 or Older with Osteoporosis. *Journal of Women's Health*. Apr 2016. PMID: 27096405.
163. Smitherman A, Wilkins T, Blatt J, **Dusetzina SB\***. Early post-therapy hospitalizations among survivors of childhood leukemia and lymphoma. *Journal of Pediatric Hematology and Oncology*. 2016 Feb 26. PMID: 26925709
164. Padula WV, Larson RA, **Dusetzina SB**, Apperley JF, Helhmann R, Bacarani M, Eigendorff E, Guilhot J, Guilhot F, Mahon F, Martinelli G, Mayer J, Müller MC, Niederwieser D, Saussele S, Schiffer CA, Karmanos BA, Silver RT, Simonsson B, Conti RM. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. *Journal of the National Cancer Institute*. 2016 Mar 4; 108(7). PMID: 26944912

165. Ellis SD, Chen RC, **Dusetzina SB**, Wheeler SB, Jackson GL, Nielsen ME, Carpenter WR, Weinberger M. Are Small Reimbursement Changes Enough to Change Cancer Care? Reimbursement Variation in Prostate Cancer Treatment. *Journal of Oncology Practice*. 2016 Mar 8. PMID: 26957651
166. Roberts MC, Weinberger M, **Dusetzina SB**, Dinan MA, Reeder-Hayes KE, Troester MA, Carey LA, Wheeler SB. Racial Variation In The Uptake Of Oncotype DX Testing For Early Stage Breast Cancer. *Journal of Clinical Oncology*. 2016 Jan 10; 34(2): 130-138. PMID: 26598755
167. **Dusetzina SB**, Keating NL. Mind the Gap: Why Closing the Doughnut Hole is Insufficient for Medicare Specialty Drug Users. *Journal of Clinical Oncology*. 2016. Feb 1; 34(4): 375-80. PMID: 26644524
168. **Dusetzina SB**, Brookhart MA, Maciejewski ML. Control Outcomes and Exposures for Improving Internal Validity of Non-Randomized Studies. *Health Services Research*. 2015 Jan. PMID:25598384
169. Roberts AW, **Dusetzina SB**, Farley JF. Revisiting the washout period in the incident user study design: why 6-12 months may not be sufficient. *Journal of Comparative Effectiveness Research*. Jan 2015; 4(1):27-35. PMID:25565067
170. Calabrese C, Overman RA, **Dusetzina SB\*\***, Hajj-Ali RA. Indeterminate QuantiFERON-TB Gold In-Tube Results in Patients with Chronic Inflammatory Diseases on Immunosuppressive Therapy. *Arthritis Care & Research*. 2014 Sep 3. PMID: 25186123
171. Stevenson DG, **Dusetzina SB**, O'Malley AJ, Mitchell SL, Zarowitz BJ, Chernew ME, Newhouse JP, Huskamp HA. High-Risk Medication Use by Nursing Home Residents Before and After Hospitalization. *Medical Care*. 2014 Oct; 52(10):884-90. PMID: 25185637.
172. **Dusetzina SB**, Muluneh B, Khan T, Richards KL, Keating NL. Obstacles to Affordable Cancer Treatments. (Invited Commentary). *NC Medical Journal*. 2014 Jul-Aug; 75(4):257-60. PMID: 25046090.
173. Stevenson DG, O'Malley AJ, **Dusetzina SB**, Chernew ME, Mitchell S, Zarowitz BJ, Newhouse JP, Huskamp HA,. Effect of Part D Coverage Restrictions for Antidepressants, Antipsychotics and Cholinesterase Inhibitors on Related Nursing Home Resident Outcomes. *Journal of the American Geriatrics Society*. 2014 Sep; 62(9): 1666-74. PMID: 25123044.
174. Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, Garrels K, Hotte S, Kattan MC, Nam R, Raghavan D, Saad F, Taplin ME, Walker-Dilks C, Williams J, Winquist E, Wooten T, **Dusetzina SB**, Virgo K. Systemic Therapy in Men with Metastatic Castration-Resistant Prostate Cancer (CRPC): American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline. *Journal of Clinical Oncology*. 2014 Oct 20; 32(30): 3436-48. PMID:25199761
175. Reeder-Hayes K, Meyer AM, **Dusetzina SB**, Liu H, Wheeler S. Racial Disparities in Initiation of Adjuvant Endocrine Therapy of Early Breast Cancer. *Breast Cancer Research and Treatment* 2014; 145(3):743-751. PMID: 24789443.
176. Pace L, **Dusetzina SB\*\***(Co-First Authors), Fendrick MA, Keating NL, Dalton VK. The impact of out-of-pocket costs on use of intrauterine contraception among women with employer-sponsored insurance. *Medical Care* 2013; 51: 959-963. PMID: 24036995



177. **Dusetzina SB**, Winn A, Abel G, Huskamp HA, Keating NL. Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia. *Journal of Clinical Oncology*. 2014 Feb 1; 32(4): 306-311. PMID: 24366936
178. **Dusetzina SB**, Mack C, Stürmer T. Propensity score estimation to address calendar time-specific channeling in comparative effectiveness research of second generation antipsychotics. *PLOS ONE*. 2013 May 7;8(5):e63973. PMID: 23667693
179. Huskamp HA, Stevenson DG, O'Malley AJ, **Dusetzina SB**, Mitchell S, Zarowitz BJ, Chernew ME, Newhouse JP. Medicare Part D plan generosity and medication use among dual-eligible nursing home residents. *Medical Care*. 2013 Oct; 51(10):894-900. PMID: 24025658
180. **Dusetzina SB**, Alexander GC, Freedman RA, Huskamp HA, Keating NL. Trends in Co-Prescribing of Antidepressants and Tamoxifen among Women with Breast Cancer, 2004-2010. *Breast Cancer Research and Treatment*. 2013. Jan; 137(1):285-96. PMID: 23149465
181. Conti RM, **Dusetzina SB**, Herbert AC, Berndt EB, Huskamp HA, Keating NL. The impact of emerging safety and effectiveness evidence on the use of physician-administered drugs: the case of bevacizumab for breast cancer. *Medical Care*. 2013 Jul; 51(7):622-627. PMID: 23605014
182. **Dusetzina SB**, Dalton VK, Chernew ME, Pace L, Bowden G, Fendrick MA. Cost of contraceptive methods to privately insured women in the United States. *Women's Health Issues*. 2013. Mar; 23(2): e69-71. PMID: 23481693
183. Ellis AR, **Dusetzina SB**, Hansen RA, Gaynes BN, Farley JF, Stürmer T. Confounding control in a nonexperimental study of STAR\*D data: logistic regression balanced covariates better than boosted CART. *Annals of Epidemiology*. 2013. Apr; 23(4):204-9. PMID: 23419508
184. Ellis AR, **Dusetzina SB**, Hansen RA, Gaynes BN, Farley JF, Stürmer T. Investigating differences in treatment effect estimates between propensity score matching and weighting: A demonstration using STAR\*D trial data. *Pharmacoepidemiology and Drug Safety*. 2013 Feb; 22(2):138-44. PMID: 23280682
185. Kornfield R, Watson S, Higashi A, Conti R, **Dusetzina SB**, Garfield CF, Dorsey ER, Huskamp HA, Alexander GC. Effect of FDA advisories on the pharmacologic treatment of Attention Deficit Hyperactivity Disorder. *Psychiatric Services*. 2013 Apr; 1;64(4):339-46. PMID: 23318985
186. **Dusetzina SB**, Cook B, Busch AB, Alexander GC, Huskamp HA. Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with Schizophrenia. *Psychiatric Services*. 2013 Jan 1;64(1):83-7. PMID: 23280461
187. **Dusetzina SB**, Busch AB, Conti RM, Donohue, JM, Alexander GC, Huskamp, HA. Changes in Antipsychotic Use among Patients with Severe Mental Illness after an FDA Advisory. *Pharmacoepidemiology and Drug Safety*. 2012 Dec; 21(12):1251-60. PMID: 22553074

188. **Dusetzina SB**, Weinberger M, Sleath B, Gaynes BN, Farley JF, Hansen RA. Prevalence of bipolar disorder diagnoses and psychotropic drug therapy among privately insured children and adolescents. *Pharmacotherapy*. 2012 Dec; 32(12):1085-94. PMID: 23208835
189. **Dusetzina SB**, Farley JF, Weinberger M, Gaynes BN, Sleath B, Hansen RA. Treatment Use and Costs among Privately-Insured Youth with New Bipolar Diagnoses. *Psychiatric Services*. 2012 Oct; 63(10):1019-25. PMID: 22855210
190. **Dusetzina SB**, Gaynes BN, Weinberger M, Farley JF, Sleath B, Hansen RA. Receipt of Guideline Concordant Pharmacotherapy among Children with New Bipolar Diagnoses. *Psychiatric Services* 2011 Dec; 62 (12): 1443-1449. PMID: 22198447
191. Gaynes BN, **Dusetzina SB**, Ellis AR, Hansen RA, Farley JF, Miller WC, Stürmer T. Treating depression after initial treatment failure: Directly comparing switch and augmenting strategies in STAR\*D. *Journal of Clinical Psychopharmacology*. 2012 Feb; 32 (1): 114-119. PMID: 22198447
192. Katz AJ, **Dusetzina SB**, Farley JF, Ellis AR, Gaynes BN, Castillo WC, Stürmer T, Hansen RA. Distressing Adverse Events After Antidepressant Switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR\*D) Trial: Influence of Adverse Events During Initial Treatment with Citalopram on Development of Subsequent Adverse Events with an Alternative Antidepressant. *Pharmacotherapy* 2012 Mar; 32 (3): 234-243. PMID: 22392456
193. Garfield CF, Dorsey ER, Zhu S, Huskamp HA, Conti R, **Dusetzina SB**, Higashi AS, Perrin JM, Alexander GC. Trends in ambulatory diagnosis and treatment of attention deficit hyperactivity disorder in the United States, 2000-2010. *Academic Pediatrics*. 2012 Feb PMID: 22326727
194. Stang PE, Ryan PB, **Dusetzina SB**, Hartzema AG, Reich C, Overhage M, Racoosin J. Health Outcomes of Interest in Observational Data: Informing the Process for Definitions in Database Networks. *Health Outcomes Research in Medicine*. 2012 Feb; 3(1):e37-344.
195. **Dusetzina SB**, Higashi AS (Co-First Authors), Dorsey RE, Conti R, Huskamp HA, Zhu S, Garfield CF, Alexander GC. Impact of FDA Risk Communications on Health Care Utilization and Health Behaviors: A Systematic Review. *Medical Care*. 2012 Jun;50(6):466-78. PMID: 22266704
196. Hansen RA, **Dusetzina SB**, Ellis AR, Stürmer T, Farley JF, Gaynes BN. Risk of adverse events in treatment resistant depression: propensity score matched comparison of antidepressant augment and switch strategies. *General Hospital Psychiatry*. 2011 Nov. PMID: 22079151
197. Gaynes BN, Farley JF, **Dusetzina SB**, Ellis AR, Hansen RA, Miller WC, Stürmer T. Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression? *Anxiety and Depression*. 2011 Nov; 28(11):989-98. PMID: 21898717
198. Hansen RA, **Dusetzina SB**, Dominik RC, Gaynes, BN. Prescription refill records as a screening tool to identify antidepressant non-adherence. *Pharmacoepidemiology and Drug Safety*. 2010 Jan;19(1):33-7. PMID: 199998397

199. Farley JF, **Dusetzina SB**. Medicaid Prescription Drug Utilization and Expenditures Following Part D. *Journal of Health Care for the Poor and Underserved*. 2010; 21 (2): 715-28. PMID: 20453368
200. Hansen RA, **Dusetzina SB**, Song L, Gaynes, BN, Tu W, Murray, MD. Depression affects adherence measurement but not the effectiveness of an adherence intervention in heart failure patients. *Journal of the American Pharmacists Association*. 2009 Nov-Dec;49(6):760-8. PMID: 19926556
201. Hansen RA, Moore CG, **Dusetzina SB**, Leinwand BI, Gartlehner G, Gaynes, BN. Controlling for Drug Dose in Systematic Review and Meta-Analysis: A Case Study of the Effect of Antidepressant Dose. *Medical Decision Making*. 2009 Jan-Feb; 29(1):91-103. PMID: 19141788

### **Refereed Reports**

National Academies of Sciences, Engineering, and Medicine. 2017. *Making Medicines Affordable: A National Imperative*. Washington, DC: The National Academies Press. Published on: 11/30/2017. doi: <https://doi.org/10.17226/24946>.

**Dusetzina SB**, Tyree S, Meyer AM, Meyer A, Green L, Carpenter WR. Linking Data for Health Services Research: A Framework and Instructional Guide. AHRQ Program on Developing Evidence to Inform Decisions about Effectiveness. Contract HHS2902010000141

### **Book Chapters**

Gross C, **Dusetzina SB**, Emanuel EJ. (Over-)Paying for Cancer Care. In: Gluck AR, Fuchs CS, editors. *A New Deal for Cancer: Lessons from a Fifty Year War*. 2021.

Muluneh B, Conti RM, Nguyen J, Cole A, Larson RA, **Dusetzina SB**. Pharmacoeconomic Considerations for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia. In: Hehlmann R, editor. *Chronic Myeloid Leukemia*, 2<sup>nd</sup> Edition. Springer Nature Switzerland AG. 2021.

Blalock, SJ, Beard, AJ, **Dusetzina, SB** Individual/Interpersonal Models of Health and Illness Behavior; In: Rickles, NM, Wertheimer AI, Smith M, editors. *Social and Behavioral Aspects of Pharmaceutical Care*, 2<sup>nd</sup>. Edition. Jones and Bartlett Publishers. Sudbury, MA. 2010.

### **Other Peer Reviewed Media**

#### **Editorials**

**Dusetzina SB**, Oberlander J. The Price of Progress: Managing Prescription Drug Spending. *J Health Polit Policy Law*. 2022 Jul 14:10041065. Epub ahead of print. PMID: 35867554.

Gross CP, **Dusetzina SB**. Stemming Medicare Spending on Discarded Drugs-Waste Not, Want Not? *JAMA Intern Med*. 2022 Dec 19. Epub ahead of print. PMID: 36534375.

Everson J, **Dusetzina SB**. Real-time Prescription Benefit Tools-The Promise and Peril. *JAMA Intern Med*. 2022 Sep 12. Epub ahead of print. PMID: 36094566.

Besaw RJ, **Dusetzina SB\***. Persistent Prescription Drug Affordability Challenges for Medicare Beneficiaries With Multiple Chronic Conditions-What Goes Up Must Come Down? *JAMA Intern Med.* 2022 Jan 4. PMID: 34982096.

Yeung K, **Dusetzina SB\***. Prescription Drug Out-of-Pocket Cost Reduction Programs: Incentives and Implications. *JAMA Intern Med.* 2021 Jun 1;181(6):765-766. PMID: 33779700.

Jazowski SA, **Dusetzina SB\***. Addressing cost-related nonadherence to oral anticancer medications through health policy reform: Challenges and opportunities. *Cancer.* 2020.

Ramsey SD, **Dusetzina SB**. Weighing Costs and Benefits in the Economics of Cancer Care. *J Clin Oncol.* 2019 Dec 5. PMID: 31804863

Winn AN, **Dusetzina SB\***. More Evidence on the Limited Impact of State Oral Oncology Parity Laws. *Cancer.* 2018 Dec 19. PMID: 30566761.

Jazowski SA, **Dusetzina SB.\*** Recommendations for Lowering Prescription Drug Spending in Public Programs. *Annals of Internal Medicine.* 2019 Nov 12. PMID: 31711129.

Mahendraratnam N, **Dusetzina SB\***. Getting More Value from Outcomes-Based Contracts. *The Journal of Law, Medicine & Ethics.* 2018;46(4):964-966. doi:10.1177/1073110518821996

Leech AA, **Dusetzina SB\***. Cost-Effective but Unaffordable: The CAR-T Conundrum. *Journal of the National Cancer Institute.* 2018 Dec 17. PMID: 30561705

**Dusetzina SB**, Alexander GC. Drug vs. class-specific black box warnings: does one bad drug spoil the bunch? *Journal of General Internal Medicine.* 2011 Jun; 26 (6): 570-572. (Editorial) PMID: 21472500

### **Blogs**

Mahendraratnam Lederer N, **Dusetzina SB**. Accelerated Approval—An Unexpected Pathway To Value-Based Pricing? *Health Affairs Blog.* 8/18/2021  
<https://www.healthaffairs.org/doi/10.1377/hblog20210812.337699/full/>

**Dusetzina SB**. Nonprofit drugmaker Civica Rx aims to cure a health care system ailment. *The Conversation.* 10/24/2018. <https://theconversation.com/nonprofit-drugmaker-civica-rx-aims-to-cure-a-health-care-system-ailment-104744>

Shafer P, **Dusetzina SB**. Looking ahead to 2018: Will a shorter open enrollment period reduce adverse selection in exchange plans? *Health Affairs Blog.* 4/14/2017  
<http://healthaffairs.org/blog/2017/04/14/looking-ahead-to-2018-will-a-shorter-open-enrollment-period-reduce-adverse-selection-in-exchange-plans/>

### **Correspondence**

Sanoff H, Lund J, O'Neil B, **Dusetzina SB**. Letter to the Editor: Immortal Time Bias or Sorafenib Effect in Elderly Patients with HCC? *Hepatology.* 2017

## **Other Non-Refereed Works**

### **Podcasts**

What the Inflation Reduction Act Really Means for Health Care

<https://www.commonwealthfund.org/publications/podcast/2022/sep/what-inflation-reduction-act-really-means-health-care>

An Arm and A Leg: Congress fixed (a piece of) Medicare. It only took a few decades.

<https://armandalegshow.com/episode/congress-fixed-a-piece-of-medicare/>

A Health Podyssey: Stacie Dusetzina Shares Why Medicare Beneficiaries May Not Fill Specialty Drug Prescriptions. Health Affairs. 2022. <https://podcasts.apple.com/us/podcast/a-health-podyssey-stacie-dusetzina-shares-why/id1542851834?i=1000558341542>

Plenary Session with Vinay Prasad, Episode 1.67

<https://www.stitcher.com/podcast/vinay-prasad/plenary-session/e/62223311>

Let's Talk High Drug Prices with Dr. Stacie Dusetzina

Spotify: <https://open.spotify.com/episode/1nyoKTvw13ryAXPiHal9n1?si=4I5hA8IUSFG9xHWSmUS3qg>

Healthcare Unfiltered. What to Expect From Medicare Part D in 2021

<https://soundcloud.com/user-565390384/what-to-expect-from-medicare-part-d-in-2021>

KHN's 'What the Health?': The Drug Price Dilemma

<https://khn.org/news/article/podcast-khn-what-the-health-199-drug-price-dilemma-june-3-2021/>

Health Affairs, A Health Podyssey: Timing Out-Of-Pocket Spending In Health Care Is Challenging

<https://www.healthaffairs.org/doi/10.1377/hp20210607.386764/full/>

**Dusetzina SB.** Financial Barriers to Cancer Care for Patients Obtaining Insurance on the Federal Exchange. Journal of Clinical Oncology Podcast for article: Access to Accredited Cancer Hospitals within Federal Exchange plans Under the Affordable Care Act. 2016.

<http://ascopubs.org/doi/suppl/10.1200/JCO.2016.69.983>

### **Essays**

Wall Street Journal April 29, 2019

*Should Drug Prices Be Disclosed in Ads Targeted Directly to Consumers? – NO*

<https://www.wsj.com/articles/should-drug-prices-be-disclosed-in-ads-targeted-directly-to-consumers-11556589840>

### **Media Collaborations**

Kaiser Health News 1/18/2019 - *Secretive 'Rebate Trap' Keeps Generic Drugs For Diabetes And Other Ills Out Of Reach.* Article includes original data.

<https://khn.org/news/secretive-rebate-trap-keeps-generic-drugs-for-diabetes-and-other-ills-out-of-reach/>

Washington Post 3/9/2016 - *This drug is defying a rare form of leukemia – and it keeps getting pricier.*

Article includes my original data and was on the front page of the print edition 3/10/2016.

[https://www.washingtonpost.com/business/this-drug-is-defying-a-rare-form-of-leukemia--and-it-keeps-getting-pricier/2016/03/09/4fff8102-c571-11e5-a4aa-f25866ba0dc6\\_story.html](https://www.washingtonpost.com/business/this-drug-is-defying-a-rare-form-of-leukemia--and-it-keeps-getting-pricier/2016/03/09/4fff8102-c571-11e5-a4aa-f25866ba0dc6_story.html)  
<http://thewashingtonpost.newspaperdirect.com/epaper/viewer.aspx>

Washington Post 3/18/2016 - A window into one of the most baffling things about drug prices. Article includes my original data.

<https://www.washingtonpost.com/news/wonk/wp/2016/03/18/a-window-into-one-of-the-most-baffling-things-about-drug-prices/>

### **Media Interviews (Selected)**

*The Inflation Reduction Act Aims to Lower Drug Costs – But Here’s How Big PHARMA Could Get Around It.* 9/20/2022. <https://www.nbcnews.com/health/health-news/inflation-reduction-act-aims-lower-drug-costs-s-big-pharma-get-rcna48341>

*What Goes Into the New ALS Drug’s High Costs?* 10/04/2022.

<https://www.politico.com/newsletters/prescription-pulse/2022/10/04/what-goes-into-the-new-als-drugs-high-cost-00060177>

*Buying From Mark Cuban’s Pharmacy Could Save Medicare Billions, Study Says.* Wall Street Journal. 06/20/2022. <https://www.wsj.com/articles/buying-from-mark-cubans-pharmacy-could-save-medicare-billions-study-says-11655758800>

*Mark Cuban’s Cost Plus Drug Company offers discounted drugs, but can it change the pharmaceutical industry?* Marketplace. 2/02/2022

<https://www.marketplace.org/2022/02/02/mark-cubans-cost-plus-drug-company-offers-discounted-drugs-but-can-it-change-the-pharmaceutical-industry/>

*The Build Back Better bill wants to lower prescription drug costs. Does it go far enough?* PBS Newshour. 11/17/2021.

<https://www.pbs.org/newshour/show/how-the-build-back-better-bill-aims-to-lower-prescription-drug-costs>

*This May Be Democrats’ Best Chance to Lower Drug Prices.* New York Times. 10/28/2021.

<https://www.nytimes.com/2021/10/27/upshot/drug-prices-democrats.html>

*The new Alzheimer’s drug is the first of its kind. Will it be the last?* Vox. 6/24/2021

<https://www.vox.com/policy-and-politics/22547044/new-alzheimers-disease-drug-aducanumab-research-science>

*EXPLAINER: How will insurers cover a new Alzheimer’s drug?* Associated Press. 06/08/2021

<https://apnews.com/article/alzheimers-drug-aduhelm-aducanumab-insurance-cost-929cead08a792217a258e278e9cef97d>

*The U.S. is buying COVID-19 vaccine for everyone. That could pave the way for drug price reform.*

Philadelphia Inquirer. 05/12/2021. <https://www.inquirer.com/health/coronavirus/coronavirus-covid-19-vaccine-cost-20210512.html>

*Pfizer Reaps Hundreds of Millions in Profits From Covid Vaccine.* New York Times. 05/05/2021.

<https://www.nytimes.com/2021/05/04/business/pfizer-covid-vaccine-profits.html>

*Leftover Pills Are Saving Lives: The Promise of Prescription Drug 'Recycling'.* 04/26/2021  
<https://www.kuaf.com/post/leftover-pills-are-saving-lives-promise-prescription-drug-recycling#stream/0>

*Holistic Drug Price Reform Deemed Vital to Avert Cost Inequities.* Bloomberg Law. 04/16/2021  
[https://www.bloomberglaw.com/bloomberglawnews/health-law-and-business/X80HVTT5000000?bna\\_news\\_filter=health-law-and-business#jcite](https://www.bloomberglaw.com/bloomberglawnews/health-law-and-business/X80HVTT5000000?bna_news_filter=health-law-and-business#jcite)

*Trump leaves behind largely unworkable drug-pricing policies.* National Journal. 1/3/2021  
<https://www.nationaljournal.com/s/711821/trump-leaves-behind-largely-unworkable-drug-policies?>

*Some companies will make big money off their COVID-19 vaccines — but not as much as they could.* CBC. 11/25/2020.  
<https://www.cbc.ca/news/business/covid-vaccine-profits-pharmaceutical-companies-pfizer-1.5812619>

*What Amazon's big pharmacy news means for US health care.* Vox. 11/23/2020.  
<https://www.vox.com/2020/11/23/21591193/amazon-pharmacy-prime-us-prescription-drug-prices>

*The Pandemic Is Showing Us How Capitalism Is Amazing, and Inadequate.* New York Times. 11/14/2020.  
<https://www.nytimes.com/2020/11/14/upshot/coronavirus-capitalism-vaccine.html>  
*Seniors waiting for Trump's \$200 debit card may not get the prescription help they hope for.* Philadelphia Inquirer. 11/2/2020. <https://www.inquirer.com/business/drugs/medicare-drug-debit-card-trump-20201102.html>

*Trump Promised Seniors Drug Discount Cards. They May Be Illegal.* New York Times. 10/22/2020.  
<https://www.nytimes.com/2020/10/22/us/politics/trump-prescription-drugs.html>

*Insurers' offers to cover COVID-19 treatment are expiring.* Marketplace. 8/21/2020.  
<https://www.marketplace.org/2020/08/21/insurers-offers-to-cover-covid-19-treatment-are-expiring/>

*The Covid-19 pandemic could be the last straw for high drug costs.* Vox. 8/12/2020.  
<https://www.vox.com/2020/8/12/21364775/covid-19-vaccine-treatment-price-poll-2020-election>

*Trump Order Tying Drug Costs to Other Countries Thin on Metrics.* Bloomberg Law. 9/15/2020.  
<https://news.bloomberglaw.com/health-law-and-business/trump-order-tying-drug-costs-to-other-countries-thin-on-metrics>

*Trump Signs Executive Orders On Drug Prices.* NPR. 7/24/2020.  
<https://www.npr.org/2020/07/24/895290378/trump-signs-executive-orders-on-drug-prices>

*When Your Insurer Drops Your Prescription Drug.* Consumer Reports. 7/02/2020.  
<https://www.consumerreports.org/prescription-drugs/when-your-insurer-drops-your-prescription-drug/>

*Marietta sues drug company over medicine that went from \$40 to \$39,000.* Atlanta Journal Constitution. 2/17/2020. <https://www.ajc.com/news/local/marietta-sues-drug-company-over-medicine-that-went-from-000/QB2iFp5ejKQ9fzbZQKYCSI/>

Early 2020 drug price hikes track lower amid political pressure. S&P Global Market Intelligence. 1/9/2020.

[https://www.spglobal.com/marketintelligence/en/news-insights/trending/idArnJKLiDRPHnS3KqPg2?utm\\_source=twitter&utm\\_medium=social&utm\\_term=edaf05ea-17b1-4a74-a7ef-a2afe9a0bc0e&utm\\_content=organic&utm\\_campaign=news](https://www.spglobal.com/marketintelligence/en/news-insights/trending/idArnJKLiDRPHnS3KqPg2?utm_source=twitter&utm_medium=social&utm_term=edaf05ea-17b1-4a74-a7ef-a2afe9a0bc0e&utm_content=organic&utm_campaign=news)

Medicare spent \$725 million on drugs that were flushed down the drain. Axios. 1/6/2020

<https://www.axios.com/prescription-drugs-medicare-thrown-away-waste-6200b388-86b7-4b01-86d9-ff1525a6d8f1.html>

The House Passed Its Prescription Drug Plan — Here's What's In It. NPR. 12/12/2019

<https://www.npr.org/sections/health-shots/2019/12/12/787190604/how-the-house-prescription-drug-plan-would-try-to-lower-drug-prices>

White House insists drug prices are falling, but critics say its report is flawed. STAT+. 10/3/2019

<https://www.statnews.com/pharmalot/2019/10/03/white-house-insists-drug-prices-are-falling-but-critics-say-its-report-is-flawed/>

How An 'International Price Index' Might Help Reduce Drug Prices. NPR. 9/19/2019

<https://www.npr.org/sections/health-shots/2019/09/19/762435585/how-an-international-price-index-might-help-reduce-drug-prices>

Drug Prices Keep Rising Amid Political Pressure, But Not As Fast. Forbes. 9/10/2019

<https://www.forbes.com/sites/leahrosenbaum/2019/09/10/drug-prices-rise-slowly/#38d468704f00>

U.S. Task Force to Recommend Wider Screening for Hepatitis C. Wall Street Journal. 8/27/2019

<https://www.wsj.com/articles/u-s-task-force-to-recommend-wider-screening-for-hepatitis-c-11566918027>

Brand-name drug prices rising at slower pace, lower amounts. CNBC. 8/19/2019

<https://www.cnbc.com/2019/08/19/brand-name-drug-prices-rising-at-slower-pace-lower-amounts.html>

Congress Overlooking Some Tactics Used to Keep Drug Prices High. Bloomberg. 7/9/2019

<https://news.bloomberglaw.com/health-law-and-business/congress-overlooking-some-tactics-used-to-keep-drug-prices-high>

Is Insulin's High Cost Keeping Diabetes Patients From Taking Their Medicine? Kaiser Health News & Politifact Healthcheck. 4/22/2019.

<https://khn.org/news/is-insulins-high-cost-keeping-diabetes-patients-from-taking-their-medicine/>

Most of the profit in the health-care industry is going to drug companies — here's why you should care. MarketWatch. 5/13/2019.

<https://www.marketwatch.com/story/most-of-the-profit-in-the-health-care-industry-is-going-to-drug-companies-heres-why-you-should-care-2019-05-13>

Medicare Spending on 22 Drugs Jumped 500% From 2013-2017. Bloomberg Government. 4/11/2019.

<https://about.bqgov.com/news/medicare-spending-jumped-500-percent/>



*Hospital pharmacists face dozens of drug shortages yearly. Reuters. 3/27/2019.*  
<https://www.reuters.com/article/us-health-rationing-drug-shortages/hospital-pharmacists-face-dozens-of-drug-shortages-yearly-idUSKCN1R827Z>

*When medicines are unaffordable, here's how patients cut costs. STAT News. 3/19/2019.*  
<https://www.statnews.com/2019/03/19/how-patients-cut-drug-costs/>

*1 big thing: Competition doesn't always drive down drug prices. Axios. 3/18/2019.*  
<https://www.axios.com/newsletters/axios-vitals-cd527be8-02e1-440c-a701-b4945e49b76a.html>

*Eli Lilly Will Sell Half-Price Version of Humalog, Its Popular Insulin. 3/4/2019.*  
<https://www.nytimes.com/2019/03/04/health/insulin-price-humalog-generic.html>

*The Prescription Drugs That Rich People Buy. New York Times. 2/7/2019.*  
<https://www.nytimes.com/2019/02/07/upshot/income-strong-predictor-drug-purchases-serious-diseases.html>

*AstraZeneca Strikes a 'Novel' Deal with a Medicare Plan to Lower Patient Out-of-Pocket Costs. STAT News. 1/28/2019.*  
<https://www.statnews.com/pharmalot/2019/01/28/astrazeneca-medicare-out-of-pocket/>

*WHO: Cancer Drugs are too Expensive. Axios. 1/25/2019.*  
<https://www.axios.com/cancer-drug-prices-world-health-organization-8c302ebd-896e-42c0-bffc-64cbaa2311a7.html>

*Medicare Part D Demo Draws Initial Praise. Politico. 1/22/2019.*  
<https://www.politico.com/newsletters/prescription-pulse/2019/01/22/praise-for-new-part-d-demo-486869>

*Prospects Cloudy for Part B Drug Payments. Medpage Today. 01/04/2019.*  
<https://www.medpagetoday.com/publichealthpolicy/healthpolicy/77250>

*Drug makers resist pressure from Washington on prices. CNN. 01/03/2019.*  
<https://www.cnn.com/2019/01/03/politics/drug-prices-trump/index.html>

*Bully Pulpit Failure? Pfizer to Increase Prices Next Year. Politico. 11/19/2018.*  
<https://www.politico.com/newsletters/prescription-pulse/2018/11/19/trumps-part-b-demo-getting-less-pushback-than-obamas-420095>

*Pharmaceutical industry challenges Trump plan forcing companies to reveal drug prices in TV ads. Washington Times. 10/25/2018.*  
<https://www.washingtontimes.com/news/2018/oct/24/trump-tv-rule-revealing-drug-prices-hit-pharmaceut/>

*Drug shortages may add \$230 million to annual U.S. drug costs. Reuters. 9/21/2018.*  
<https://www.reuters.com/article/us-health-drug-shortages-pricing/drug-shortages-may-add-230-million-to-annual-u-s-drug-costs-idUSKCN1M12LC>

*Fewer middle-aged stroke survivors skip medicines under Obamacare.* Reuters. 8/27/2018.  
<https://www.reuters.com/article/us-health-stroke-insurance/fewer-middle-aged-stroke-survivors-skip-medicines-under-obamacare-idUSKCN1LC253>

*Companies moving to cut out middlemen and reduce drug prices for employees.* MarketWatch. 8/28/2018  
<https://www.marketwatch.com/story/companies-moving-to-cut-out-middlemen-and-reduce-drug-prices-for-employees-2018-08-28>

*Brand-name combo pills may cost more than getting drugs separately.* Reuters. 8/21/2018.  
<https://www.reuters.com/article/us-health-medicare-spending/brand-name-combo-pills-may-cost-more-than-getting-drugs-separately-idUSKCN1L61ZU>

*Medicare patients may lower drug costs by not using their insurance.* Reuters. 7/23/2018  
<https://www.reuters.com/article/us-health-drug-costs-generics/medicare-patients-may-lower-drug-costs-by-not-using-their-insurance-idUSKBN1KD2IX>

*Pharmacy middlemen steer some patients to riskier drugs.* Press Herald. 7/08/2018  
<https://www.pressherald.com/2018/07/08/pharmacy-middlemen-steer-some-patients-to-riskier-drugs/>

*The Health 202: 'Gag clauses' mean you might be paying more for prescription drugs than you need to.* The Washington Post. 7/05/2018  
[https://www.washingtonpost.com/news/powerpost/paloma/the-health-202/2018/07/05/the-health-202-gag-clauses-mean-you-might-be-paying-more-for-prescription-drugs-than-you-need-to/5b3a36ca1b326b3348addc4a/?utm\\_term=.d720cfb2e853](https://www.washingtonpost.com/news/powerpost/paloma/the-health-202/2018/07/05/the-health-202-gag-clauses-mean-you-might-be-paying-more-for-prescription-drugs-than-you-need-to/5b3a36ca1b326b3348addc4a/?utm_term=.d720cfb2e853)

*Drugmakers defy Trump's call to drop prices.* Politico. 7/03/2018  
<https://www.politico.com/story/2018/07/03/drugmakers-trump-drug-prices-668260>

*Has Nevada's diabetes drug transparency law lost its steam?* Politico Pulse. 7/02/2018  
<https://www.politico.com/newsletters/prescription-pulse/2018/07/02/perverse-incentives-why-some-340b-pharmacies-are-opting-for-branded-drugs-268802>

*Amazon acquires PillPack as it muscled its way into the health care industry.* Marketplace. 6/28/2018  
<https://www.marketplace.org/2018/06/28/health-care/amazon-getting-pill-business>

*Trump's big campaign promise on drug prices wouldn't have worked, Health and Human Services secretary says.* Washington Post, 5/14/2018  
[https://www.washingtonpost.com/news/wonk/wp/2018/05/14/trumps-big-campaign-promise-on-drug-prices-wouldnt-have-worked-health-and-human-services-secretary-says/?utm\\_term=.ef599aa1bc24](https://www.washingtonpost.com/news/wonk/wp/2018/05/14/trumps-big-campaign-promise-on-drug-prices-wouldnt-have-worked-health-and-human-services-secretary-says/?utm_term=.ef599aa1bc24)

*The 5 most expensive drugs in the United States.* CNN, 5/11/2018  
<https://www.cnn.com/2018/05/11/health/most-expensive-prescription-drugs/index.html>

*Trump Vows (Again) To Lower Drug Prices But Skeptics Doubt Much Will Change.* Kaiser Health News, 5/11/2018  
<https://khn.org/news/trump-vows-again-to-bring-down-drug-prices-but-skeptics-doubt-much-will-change/>

*Why Did Novartis Pay Trump's Lawyer \$1.2 Million? Look At Its Drug Prices. Kaiser Health News, 5/11/2018*

<https://khn.org/news/why-the-drugmaker-that-paid-trumps-lawyer-1-2-million-is-so-worried/>

*Women With Breast Cancer Delay Care When Faced With High Deductibles. The New York Times, 5/04/2018.* <https://www.nytimes.com/2018/05/04/health/breast-cancer-insurance-deductibles.html>

*Capping out-of-pocket drug costs for Medicare patients wouldn't lower drug prices. Marketplace, 4/30/2018.* <https://www.marketplace.org/2018/05/01/health-care/capping-out-pocket-drug-costs-medicare-patients-wouldnt-lower-drug-prices>

*Science hinted that cancer patients could take less of a \$148,000-a-year drug. Its maker tripled the price of a pill. Washington Post, 4/18/2018*

[https://www.washingtonpost.com/news/wonk/wp/2018/04/18/science-hinted-that-cancer-patients-could-take-less-of-a-148000-a-year-drug-the-company-tripled-the-price-of-a-pill/?utm\\_term=.9605fbc1a890](https://www.washingtonpost.com/news/wonk/wp/2018/04/18/science-hinted-that-cancer-patients-could-take-less-of-a-148000-a-year-drug-the-company-tripled-the-price-of-a-pill/?utm_term=.9605fbc1a890)

*Drug copays sometimes exceed costs, Reuters, 03/13/2018*

<https://uk.reuters.com/article/us-health-medicines-copays/drug-copays-sometimes-exceed-costs-idUKKCN1GP2P4>

*Trump's drug pricing proposals get lukewarm reaction, POLITICO, 02/13/2018*

<https://www.politico.com/newsletters/politico-pulse/2018/02/13/trumps-budget-targets-health-programs-103470>

*Expensive specialty drugs are forcing seniors to make hard choices, Washington Post, 11/10/2017*

[https://www.washingtonpost.com/news/wonk/wp/2017/11/10/expensive-specialty-drugs-are-forcing-seniors-to-make-hard-choices/?utm\\_term=.e2b0d846fced](https://www.washingtonpost.com/news/wonk/wp/2017/11/10/expensive-specialty-drugs-are-forcing-seniors-to-make-hard-choices/?utm_term=.e2b0d846fced)

*Medicare patients face high costs for newer injected cholesterol drugs, Reuters, 09/29/2017*

<http://www.reuters.com/article/us-health-costs-pcsk9-inhibitors/medicare-patients-face-high-costs-for-newer-injected-cholesterol-drugs-idUSKCN1C42OK>

*Whichever Way 'Repeal And Replace' Blows, Pharma Is Due For Windfall. Kaiser Health News, 07/12/2017*

<http://khn.org/news/whichever-way-repeal-and-replace-blows-pharma-is-due-for-windfall/>

*Continuing the conversation on drug prices. Politico. 07/11/2017*

<https://www.politico.com/tipsheets/morning-ehealth/2017/07/11/house-to-move-on-fda-user-fees-wednesday-221264>

*Heart healthy lifestyle tied to lower drug costs. Reuters, 06/22/2017*

<http://www.reuters.com/article/us-health-heartdisease-drug-spending-idUSKBN19C2WC>

*Breast cancer treatment costs higher for younger women. Reuters, 05/11/2017*

<http://www.reuters.com/article/us-health-breastcancer-costs-idUSKBN1872WO>

*Inside the overlooked battle between drug makers and insurers over chemotherapy. STAT News, 03/31/2017*

<https://www.statnews.com/2017/03/31/drug-makers-insurers-chemotherapy/>

*As Drug Costs Soar, People Delay Or Skip Cancer Treatments.* NPR / Kaiser Health News, 03/15/2017  
<http://www.npr.org/sections/health-shots/2017/03/15/520110742/as-drug-costs-soar-people-delay-or-skip-cancer-treatments>

*Company-funded studies of approved drugs may not catch safety issues.* Reuters, 02/20/2017  
<http://www.reuters.com/article/us-health-medicines-safety-idUSKBN15Z1X5>

*Medicare subsidies may help more women stick with breast cancer drugs.* Reuters, 10/19/2016  
<http://www.reuters.com/article/us-health-medicarepartd-breast-cancer-idUSKCN12J2FX>

*Breast cancer chemo costs vary despite similar effectiveness.* Reuters, 10/10/2016  
<http://uk.reuters.com/article/us-health-breastcancer-drug-costs-idUKKCN12A2H9>

*Steep Rise in Price of Older Cancer Drugs.* Health Day 10/06/2016  
<https://consumer.healthday.com/senior-citizen-information-31/medicare-news-422/steep-rise-in-price-of-older-cancer-drugs-could-harm-patients-715606.html>

*Can anything contain U.S. drug costs?* Reuters and NBC News, 08/23/2016  
<http://www.reuters.com/article/us-health-drugcosts-idUSKCN10Y23E>  
<http://www.nbcnews.com/health/health-news/what-s-blame-high-u-s-drug-costs-n636696>

*U.S. spends \$3 billion a year on unused cancer drugs.* Reuters, 03/26/2016  
<http://www.reuters.com/article/us-health-costs-drug-waste-idUSKCNOWR1AC>

*The U.S. throws out \$3 billion in cancer drugs every year.* Huffington Post, 03/28/2016  
[http://www.huffingtonpost.com/entry/the-us-throws-out-3-billion-dollars-in-cancer-drugs-every-year\\_us\\_56f94e45e4b0a372181a62ae](http://www.huffingtonpost.com/entry/the-us-throws-out-3-billion-dollars-in-cancer-drugs-every-year_us_56f94e45e4b0a372181a62ae)

*For cancer survivors, expenses keep mounting.* Health Day, 01/12/2016  
[https://www.nlm.nih.gov/medlineplus/news/fullstory\\_156652.html](https://www.nlm.nih.gov/medlineplus/news/fullstory_156652.html)

*Use of antidepressants and breast cancer recurrence.* The Lancet Oncology News, 12/11/2015.  
<http://www.sciencedirect.com/science/article/pii/S1470204515005756>

*Breast cancer treatment costs hard to nail down.* USA Today, 10/3/2015.  
<http://www.usatoday.com/story/news/nation-now/2015/10/03/breast-cancer-costs-hard-nail/73292584/>

*Docs concerned about cancer drug prices, but solutions might be elusive.* Triangle Business Journal, 8/4/2015. <http://www.bizjournals.com/triangle/news/2015/08/04/docs-concerned-about-cancer-drug-prices.html>

*A growing risk: High-deductible health plans can ruin finances.* The Charlotte Observer, 4/4/2015.  
<http://www.charlotteobserver.com/news/business/health-care/article17398751.html>

**Podium Presentations (\* Indicates Role as Faculty Mentor)**

**Includes only presentations as first author or of trainees.**

**Dusetzina SB**, Huskamp HA, Rothman RL, Pinheiro LC, Roberts AW, Shah ND, Walunas TL, Wood WA, Zuckerman AD, Zullig LL, Keating NL. Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions. European Health Economics Meeting. Oslo, Norway. July 2022.

**Dusetzina SB**. Achieving Pharmacoequity - a Policy Prescription for Reducing Health Disparities (Invited Panelist). AcademyHealth Annual Research Meeting. Washington DC. June 2022.

**Dusetzina SB**, Huskamp HA, Rothman RL, Pinheiro LC, Roberts AW, Shah ND, Walunas TL, Wood WA, Zuckerman AD, Zullig LL, Keating NL. Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions. AcademyHealth Annual Research Meeting. Washington DC. June 2022.

**Dusetzina SB**, Huskamp HA, Jazowski S, Winn AN, Basch E, Keating NL. Comparing Anticancer Medication Use and Spending Under Oncology Parity Laws with Versus without out-of-Pocket Spending Caps. 10th Annual Conference of the American Society of Health Economists. June 2021.

**Dusetzina SB**, Sarpatwari A, Carrier M, Hansen R, Keating NL, Huskamp HA. Authorized Generic Drug Coverage and Estimated Spending Under Medicare Part D. 10th Annual Conference of the American Society of Health Economists. June 2021.

**Dusetzina SB**, Huskamp HA, Keohane LM, Keating NL. Policy Options for Improving Insulin Affordability in the United States. 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Berlin, Germany. (Oral Presentation Accepted; Cancelled Due to COVID19)

**Dusetzina SB**, Cubanski J, Nshuti L, True S, Hoadley J, Roberts D, Neuman T. Coverage of Brand-Name Drugs When Generics are Available in the United States. 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Berlin, Germany. (Oral Presentation Accepted; Cancelled Due to COVID19)

**Dusetzina SB**, Huskamp HA, Keohane LM, Keating NL. Policy Options for Improving Insulin Affordability in the United States. European Health Economics Association Conference 2020. July 2020. Oslo, Norway. (Oral Presentation Accepted; Cancelled Due to COVID19)

**Dusetzina SB**, Cubanski J, Nshuti L, True S, Hoadley J, Roberts D, Neuman T. Coverage of Brand-Name Drugs When Generics are Available in the United States. European Health Economics Association Conference 2020. July 2020. Oslo, Norway. (Oral Presentation Accepted; Cancelled Due to COVID19)

**Dusetzina SB**. (Invited Panelist): The out of Pocket Cost Crisis: How Can Researchers, Clinicians, and Policymakers Bring Affordability Back to Healthcare? AcademyHealth Annual Research Meeting. Washington DC. (Cancelled Due to COVID19)

**Dusetzina SB**. Huskamp HA, Keating NL. Specialty Drug Pricing, Coverage, and out-of-Pocket Spending on Orally-Administered Anticancer Drugs in Part D, 2010 to 2018. Association for Public Policy Analysis & Management Meeting, November 2019, Denver, CO.

**Dusetzina SB.** Huskamp HA, Keating NL. Specialty Drug Pricing, Coverage, and out-of-Pocket Spending on Orally-Administered Anticancer Drugs in Part D, 2010 to 2018. AcademyHealth Annual Research Meeting, June 2, 2019, Washington D.C.

Jazowski SA, Patrick SW, **Dusetzina SB.\*** Identifying Off-Label Pharmaceutical Company Promotion of Opioids for Cancer Pain Management. 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Prague, Czech Republic. August 22-26, 2018.

**Dusetzina SB.** (Invited Panel with Michelle Mello, Diane Rowland, Brendan Saloner) Ensuring Access to Affordable Prescription Drugs—the National Academies of Sciences, Engineering and Medicine’s Report. AcademyHealth Annual Research Meeting, June 24, 2018, Seattle, WA.

**Dusetzina SB,** Jazowski SA, Cole, AL, Nguyen J. Coverage and out-of-Pocket Spending on Brand Versus Generic/Biosimilar Specialty Drugs in Medicare Part D. American Society of Health Economists. Atlanta, GA, June 10-13, 2018.

**Dusetzina SB.** (Invited Panel) An Overview of the National Academy’s Recommendation on Drug Access. ASCO Pre-Annual Meeting Seminar: Economics of Cancer Care. American Society of Clinical Oncology Annual Meeting, Chicago, IL, May 31, 2018.

**Dusetzina SB.** (Invited Panel with Norman Augustine, Robert Dubois, Guru Madhavan, Charles Phelps) Making Medicines Affordable: A National Imperative. Reflections on the National Academies Report. ISPOR 23<sup>rd</sup> Annual International Meeting, Baltimore, MD. May 22, 2018.

**Dusetzina SB.** (Invited Panel) Out-of-Pocket Spending and Adherence to Medications. ASCO Pre-Annual Meeting Seminar: Economics of Cancer Care, Financial Toxicity and Cost. American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 1, 2017.

Mitchell A, Winn AN, **Dusetzina SB\*.** Pharmaceutical Industry Payments and Physician Drug Selection in Oncology. American Society of Clinical Oncology Annual Meeting, June 2-6, Chicago, IL (*Awarded Best Abstract in Category*).

Mitchell A, Winn AN, **Dusetzina SB\*.** Pharmaceutical Industry Payments and Physician Drug Selection in Oncology. AcademyHealth Annual Research Meeting, Jun 25-27, New Orleans, LA.

Winn AN, **Dusetzina SB\*.** Paying More for the Same Care: Comparing Physician Office and Hospital Outpatient Department Spending for Infused Chemotherapy among Privately Insured Patients. AcademyHealth Annual Research Meeting, Jun 25-27, New Orleans, LA.

**Dusetzina SB.** Trends in Specialty Drug Spending and Use in Commercial Health Plans in the United States: 2003-2014. 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Dublin, Ireland, August 28, 2016.

Winn AN, **Dusetzina SB\*.** A Complimentary Approach to Group Based Trajectory Models. 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Dublin, Ireland, August 28, 2016.

**Dusetzina SB**, Huskamp HA, Winn AN, Basch EB, Keating NL. The Impact of State Chemotherapy Parity Laws on Use and Spending for Oral Chemotherapy. 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Dublin, Ireland, August 26, 2016.

Mahendraratnam N, **Dusetzina SB**, Farley JF. Early Impact of Medicaid Expansion on Prescription Drug Utilization and Spending. International Society for Pharmacoeconomics and Outcomes Research, Washington D.C., May 2016. *Podium Award Finalist*.

**Dusetzina SB**, Huskamp HA, Winn AN, Basch EB, Keating NL. The Impact of State Chemotherapy Parity Laws on Use and Spending for Oral Chemotherapy. American Society of Health Economists, Philadelphia, PA, June 2016.

**Dusetzina SB**, Winn AN, Reeder-Hayes K, Maciejewski ML. Taking Medication Adherence Personally: What Does Prior Adherence Tell Us about Future Adherence? 31<sup>st</sup> International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA, August 25, 2015.

Winn AN, **Dusetzina SB**. \* Improving Adherence Measurement for Applied Pharmacoepidemiology: Estimating the Association between Endocrine Therapy Adherence and Mortality among Women with Breast Cancer. AcademyHealth Annual Research Meeting, Minneapolis, MN. June 14-16, 2015.

Check DK, Samuel C, Rosenstein DL, **Dusetzina SB**\*. Racial Differences in Early Symptom Management, Hospice Use, and Intensity of End-of-Life Care among Elderly Women with Breast Cancer. AcademyHealth Annual Research Meeting, Minneapolis, MN. June 14-16, 2015.

Check DK, Samuel C, Rosenstein DL, **Dusetzina SB**\*. Racial Differences in Early Symptom Management, Hospice Use, and Intensity of End-of-Life Care among Elderly Women with Breast Cancer. Multinational Association of Supportive Care in Cancer, Copenhagen Denmark. June 25-27, 2015.

**Dusetzina SB**, Ellis SD, Freedman RA, Winn A, Chambers J, Conti RM, Alexander GC, Huskamp HA, Keating NL. Payer-Level Differences in the Response to Regulatory Actions Regarding Bevacizumab's Breast Cancer Indication Withdrawal. 30<sup>th</sup> International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Taipei, Taiwan, October 25, 2014.

**Dusetzina SB**, Tyree S, Meyer AM, Meyer A, Green L, Carpenter WR. Performance of Methods for Linking Registry Data to Insurance Claims when Unique Identifiers are Unavailable. 30<sup>th</sup> International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Taipei, Taiwan, Oct 27, 2014.

Jolles MP, Haynes-Maslow L, Roberts M, **Dusetzina SB**. \* Mental Health Service Use by Race and Ethnicity for Adult Patients with Co-occurring Chronic Health Care Needs, 2007-2010. AcademyHealth Annual Research Meeting, San Diego, CA. June 7-10, 2014.

**Dusetzina SB**, Gaynes BN, Brookhart MA, Sturmer T, Johnsson-Funk M, Huskamp HA. Using Administrative Data to Evaluate the Clinical Equivalence of Generic versus Branded Bupropion. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, Canada, August 15-28, 2013.

**Dusetzina SB**, Alexander GC, Freedman RA, Huskamp HA, Keating NL. Trends in Co-Prescribing of Antidepressants and Tamoxifen among Women with Breast Cancer, 2004-2010. 28<sup>th</sup> International

Conference on Pharmacoepidemiology & Therapeutic Risk Management, Barcelona, Spain. Aug 24, 2012.

**Dusetzina SB**, Higashi AS, Dorsey RE, Conti R, Huskamp HA, Zhu S, Garfield CF, Alexander GC. Impact of FDA Risk Communications on Health Care Utilization and Health Behaviors: A Systematic Review. American Public Health Association Annual Meeting, Washington DC, November 2, 2011.

**Dusetzina SB**, Busch AB, Conti RM, Donohue JM, Alexander GC, Huskamp HA. Changes in the Use of High Metabolic Risk Antipsychotics. 27th ICPE: International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Chicago IL August 14-17,2011.

**Dusetzina SB**, Gaynes BN, Farley JF, Weinberger M, Sleath BL, Hansen RA. Bipolar Spectrum Disorders in Commercially Insured Children: Prevalence of Diagnoses and Treatments Received. Academy Health Annual Research Meeting, Boston, MA. June 29, 2010.

**Dusetzina SB**, Gaynes BN, Farley JF, Weinberger M, Sleath BL, Hansen RA. The Quality of Initial Medication Prescribing for Children with Bipolar I Disorder. National Research Service Award Trainees Meeting, Boston, MA. June 25, 2010.

**Dusetzina SB**, Hansen RA, Dominik R, Gaynes BN. Prescription Refill Records as a Screening Tool to Identify Antidepressant Non-Adherence. American Pharmacists Association (APhA) Annual Meeting & Exposition, San Antonio, TX. April 3 – 6, 2009.

**Dusetzina SB**, Farley JF, Hansen RA, Relationship between State Medicaid Copayment Policies and Prescription Drug Utilization. Southern Pharmacy Administration Conference; Little Rock, Arkansas. June 15-17, 2007.

**Poster Presentations (\* Indicates Role as Faculty Mentor)**  
**Includes only presentations as first author or of trainees.**

Baig K, **Dusetzina SB\***. Is the Senior Savings Model Incentivizing Insulin Users to Enroll in Medicare Advantage Plans? Academy Health Annual Research Meeting, June 4-7, 2022, Washington, DC.

Jazowski SA, Huskamp HA, Keating NL, Wood WA, **Dusetzina SB\***. Non-Initiation of Prescribed Orally-Administered Therapy for Hematologic Malignancies. Academy Health Annual Research Meeting, June 4-7, 2022, Washington, DC.

Jazowski S, Wilson L, **Dusetzina SB\***, Zafar Y, Zullig L. The Role of High-Deductible Health Plans on the Use of Lenalidomide in Multiple Myeloma. AcademyHealth Annual Research Meeting. June 2021 (Virtual)

Jazowski S, Samuel-Ryals C, Wood W, Zullig L, Trogdon J, **Dusetzina SB\***. Do Medicare Part D Low-Income Subsidies Narrow Disparities in Orally-Administered Antimyeloma Treatment Initiation? AcademyHealth Annual Research Meeting. June 2021 (Virtual)

Jazowski SA, Patrick SW, **Dusetzina SB.\*** The Rise and Fall of Prescription Fentanyl. International Conference on Pharmacoepidemiology & Therapeutic Risk Management 2020 All Access. September 16-17, 2020. Virtual; in-person meeting canceled due to COVID-19.



Jazowski SA, Nshuti L, **Dusetzina SB**.\* Trends in Formulary Coverage and Point-of-Sale Prices of Filgrastim Products. International Conference on Pharmacoepidemiology & Therapeutic Risk Management 2020 All Access. September 16-17, 2020. Virtual; in-person meeting canceled due to COVID-19. Spotlight Poster Winner in the Biologics and Biosimilars Category.

Jazowski SA, Wilson L, **Dusetzina SB**,\* Zafar SY, Zullig LL. Role of High-Deductible Health Plans on the Use of Lenalidomide. International Conference on Pharmacoepidemiology & Therapeutic Risk Management 2020. Sept 16-17, 2020. Virtual; in-person meeting canceled due to COVID-19.

Jazowski SA, **Dusetzina SB**.\* Trends in the Promotion and Utilization of Programmed Death Receptor-1 Blocking Antibodies. Thomas M. Carsey Graduate Student Symposium. Chapel Hill, NC. November 8, 2019.

Jazowski SA, **Dusetzina SB**.\* Trends in the Utilization of Short-acting Filgrastim following the United States Market Launch of the First Biosimilar. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Philadelphia, PA. August 24-28, 2019.

Jazowski SA, **Dusetzina SB**.\* Trends in the Promotion and Utilization of Programmed Death Receptor-1 Blocking Antibodies. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Philadelphia, PA. August 24-28, 2019.

Winn AN, Keating NL, Trogdon J, Basch E, **Dusetzina SB**\*. Association between Chemotherapy Provider Competition and Access, Cost and Quality of Care for Medicare Beneficiaries with Cancer. AcademyHealth Annual Research Meeting, June 25, 2018, Seattle, WA.

Mitchell A, Winn AN, **Dusetzina SB**\*. Temporal Association of Industry Payments and Prescribing Changes in Oncology. AcademyHealth Annual Research Meeting, June 25, 2018, Seattle, WA.

Mitchell A, Kinlaw A, Sanoff HK, Basch E, Lund J, Peacock-Hinton S, **Dusetzina SB**\*. Cancer Patients Receive Higher-Priced Chemotherapy When Treated in Private Practice Compared to Academic Institutions. AcademyHealth Annual Research Meeting, June 25, 2018, Seattle, WA.

Jazowski SA, **Dusetzina SB**\*. Identifying Off-Label Promotion of Cancer Pain Management Opioids in Open Payments. AcademyHealth Annual Research Meeting, June 25, 2018, Seattle, WA.

Higginbotham L, Jazowski SA, Adamson A, **Dusetzina SB**\*. Uptake of Immunotherapy Among Medicare Beneficiaries with Advanced Melanoma. AcademyHealth Annual Research Meeting, June 24, 2018, Seattle, WA.

**Dusetzina SB**, Jazowski SA, Cole, AL, Nguyen J. Coverage and out-of-Pocket Spending on Brand Versus Generic/Biosimilar Specialty Drugs in Medicare Part D. AcademyHealth Annual Research Meeting, June 24, 2018, Seattle, WA.

Savitz S, Trogdon J, Bailey S, Jones S, **Dusetzina SB**, Stearns S. Evaluation of Patient-Clinician Communicating during Decision Making for Stable Angina. AcademyHealth Annual Research Meeting, June 24, 2018, Seattle, WA.

**Dusetzina SB**, Owino H, Ansari S, Glickman SW. Post-Discharge Medicaid Spending and Health Services Use for Patients with Serious Mental Illness Treated at an Emergency Department Versus a Dedicated

Community Mental Health Center. AcademyHealth Annual Research Meeting, Jun 25-27, New Orleans, LA

Roberts A, Saloner B, **Dusetzina SB**. Utilization and Costs of Buprenorphine for Opioid Use Disorder: Trends from 2003-2015. AcademyHealth Annual Research Meeting, Jun 25-27, New Orleans, LA.

Olszewski AJ, **Dusetzina SB**, Davidoff AJ, Trivedi AN. Closure of Medicare Part D Coverage Gap by the Affordable Care Act and Use of Oral Anti-Myeloma Agents. American Society of Clinical Oncology Annual Meeting, June 2-6, Chicago, IL.

Rotenstein L, **Dusetzina SB**, Keating NL. Out-of-Pocket Spending Not Associated with Drug Value for Oral Oncolytics Reimbursed By Commercial Insurers, 2007-2014. American Society of Clinical Oncology Annual Meeting, June 2-6, Chicago, IL. (Poster Discussion Selection)

Roberts M, **Dusetzina SB\***. The Effect of a Celebrity Health Disclosure on Demand for Health Care: Trends in BRCA Testing and Subsequent Health Services Use. American Society of Prevention Oncology. March 12-14, 2017 at the Grand Hyatt Hotel in Seattle, Washington.

Barber EL, Van Le L, **Dusetzina SB\***. Neoadjuvant chemotherapy versus primary debulking surgery: A propensity score matched cohort analysis of survival. Society of Gynecologic Oncology SGO 48th Annual Meeting on Women's Cancer. March 11-15, 2017, National Harbor, MD.

Smitherman AB, Mohabir D, Wilkins TM, Blatt J, Nichols HB, **Dusetzina SB\***. Early Post-therapy Prescription Drug Usage among Survivors of Childhood Cancers. ASCO Cancer Survivorship Symposium. January 27-28, 2017. San Diego, CA.

Chou Y, **Dusetzina SB\***. Trends in Erlotinib Use for Non-Small Cell Lung Cancer, 2007-2012. 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Dublin, Ireland, August 26, 2016.

Cole AL, Sanoff HK, **Dusetzina SB.\*** Uptake and Cost of Capecitabine versus 5-FU Among Commercially-Insured Colorectal Cancer Patients. 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Dublin, Ireland, August 26, 2016.

Cole AL, Sanoff HK, **Dusetzina SB.\*** Uptake and cost of capecitabine among commercially-insured colorectal cancer patients. International Society for Pharmacoeconomics and Outcomes Research, Washington D.C., May 2016. *Poster Award Finalist*.

Cole AL, Sanoff HK, **Dusetzina SB.\*** Uptake and cost of capecitabine among commercially-insured colorectal cancer patients. UNC Eshelman School of Pharmacy Graduate Student Receipt, April 2016. *Poster Award Winner, 2<sup>nd</sup> Place*.

Winn AN, Keating NL, **Dusetzina SB\***. Factors Associated with the Initiation and Use of Tyrosine Kinase Inhibitors Among Medicare Beneficiaries with Chronic Myeloid Leukemia. Academy Health Annual Research Meeting, Boston, MA. June 27, 2016.

Mahendraratnam N, **Dusetzina SB**, Farley JF. Early Impact of Medicaid Expansion on Prescription Drug Utilization and Spending. Academy Health Annual Research Meeting, Boston, MA. June 27, 2016.

Mitchell A, Basch EM, **Dusetzina SB\***. Financial ties to industry are prevalent among National Comprehensive Cancer Network guideline authors. American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 4, 2016 (Poster Discussion Selection).

Falchook AD, Fang T, **Dusetzina SB**, Basak R, Hanson L, Selvam N, Chen RC. Use of Supportive Care at End-of-Life for Patients Younger than 65 with Incurable Cancer. American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 4, 2016 (Poster Discussion Selection).

Knight TG, Deal AM, Muss HB, **Dusetzina SB**, Chol SK, Bensen JT, Williams GR. Financial distress among older versus younger adults with cancer. American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 4, 2016.

Kilfoyle KA, Rahangdale L, **Dusetzina SB\***. Human papillomavirus (HPV) vaccine uptake among commercially insured postpartum women, 2006 – 2012. American Congress of Obstetricians and Gynecologists, Washington D.C., May 14-17, 2016.

Check DK, Reeder-Hayes KE, Basch EM, Zullig LL, Weinberger M, **Dusetzina SB\***. Investigating Racial Disparities in Use of NK1 Receptor Antagonists to Prevent Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer. American Society of Clinical Oncology Quality Care Symposium, Phoenix, AZ, February 26-27, 2016.

Chou Y, Rosenstein DL, **Dusetzina SB\***. Stage-Specific Incident Antidepressant Use and Adherence among Older Women with Breast Cancer. AcademyHealth, Minneapolis, MN. June 14-16, 2015

Chou Y, Winn AN, Rosenstein DL, **Dusetzina SB\***. Estimating the Impact of a Breast Cancer Diagnosis on Antidepressant Adherence. 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA, August 2015

Check DK, Samuel C, Rosenstein DL, **Dusetzina SB\***. The Association Between Early Symptom Management, Hospice Use, and Intensity of End-of-Life Care Among Elderly Women with Breast Cancer. AcademyHealth, Minneapolis, MN. June 14-16, 2015

**Dusetzina SB**, Tyree S, Meyer AM, Carpenter WR. Performance of Methods for Linking Registry Data to Insurance Claims when Unique Identifiers are Unavailable. AcademyHealth, San Diego, CA. June 7-10, 2014.

Roberts M, **Dusetzina SB.\*** Trends in Oncotype DX use and per-use patient and insurer costs. AcademyHealth, San Diego, CA. June 7-10, 2014.

Lewis SE, Liu T, **Dusetzina SB.\*** The Association between Age and Receipt of Comprehensive Diabetes Care. AcademyHealth Annual Research Meeting, San Diego, CA. June 7-10, 2014.

Stevenson DG, **Dusetzina SB**, O'Malley AJ, Mitchell SL, Zarowitz BJ, Chernew ME, Newhouse JP, Huskamp HA. Potentially Inappropriate Medication Use as Nursing Home Residents Transition between the Hospital and Nursing Home. AcademyHealth, San Diego, CA. June 7-10, 2014.

Winn A, Keating NL, Lin P, Huskamp HA, **Dusetzina SB\*** Orally Administered Cancer Drugs for Medicare Beneficiaries: Implications for Out-of-Pocket Spending Among Patients with Chronic Myeloid Leukemia. AcademyHealth Annual Research Meeting, San Diego, CA. June 7-10, 2014.

Kum H, Krishnamurthy A, **Dusetzina SB**. Privacy-preserving Interactive Record Linkage: Privacy beyond Anonymity. AcademyHealth Annual Research Meeting, San Diego, CA. June 7-10, 2014.

**Dusetzina SB**, Mack C, Stürmer T. The Impact of Time Specific-Propensity Score Estimation on Estimates of the Comparative Effectiveness of Second Generation Antipsychotics. 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, Canada, Aug 15-28, 2013.

**Dusetzina SB**, Mack C, Stürmer T. The Impact of Time Specific-Propensity Score Estimation on Estimates of the Comparative Effectiveness of Second Generation Antipsychotics. Academy Health Annual Research Meeting, Baltimore, MD. June 24, 2013.

**Dusetzina SB**, Gaynes BN, Farley JF, Weinberger M, Sleath BL, Hansen RA. The Quality of Initial Medication Prescribing for Children with Bipolar I Disorder 27th ICPE: International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Chicago IL August 14-17, 2011.

**Dusetzina SB**, Gaynes BN, Farley JF, Weinberger M, Sleath BL, Hansen RA. Age Related Treatment Differences Among Children with Bipolar Spectrum Disorders. International Society of Pharmacoeconomics and Outcomes Research Meeting, Atlanta, GA. May 15-19, 2010.

**Dusetzina SB**, Hansen RA, Pudlo A, Gaynes BN. The Feasibility of a Community Pharmacy-Based Intervention to Reduce Barriers to Antidepressant Adherence - Lessons Learned from a Pilot Study National Research Service Award Trainees Meeting, Chicago, IL. June 27- 30, 2009.

**Dusetzina SB**, Hansen RA, Song L, Gaynes, BN, Tu W, Murray MD. Depression Affects Adherence Measurement but Not the Effectiveness of an Adherence Intervention in Heart Failure Patients. American Pharmacists Association Annual Meeting, San Antonio, TX. April 3 – 6, 2009.

**Dusetzina SB**, Farley JF. The Influence of Medicare Part D on Medicaid Prescription Expenditures and Utilization. American Pharmacists Association Annual Meeting, San Diego, California. Mar 14 – 17, 2008.

#### **f) Teaching Activities**

PhD Program Director, Health Policy (Vanderbilt)	2019 - Present
Research Immersion Area Lead (Vanderbilt University School of Medicine)	2020 - Present

#### **Vanderbilt University School of Medicine**

<b>Term</b>	<b>Course number, title, type</b>	<b>Enrollment</b>	<b>Responsibility</b>
Spring 2022	HPOL 8540: Introduction to Healthcare Database Research	12	Course Director 36 contact hours
Spring 2022	Foundations in Health Policy	90	2 lecture hours

Fall 2021	Clinical Informatics	25	Instructor
Spring 2019, 2020, 2021, 2022	Drug and Device Course, Vanderbilt School of Medicine	20	Instructor 1 lecture hour
Fall 2019, 2020, 2021	Financial Toxicity and Access to Care (University of Tennessee College of Pharmacy)	50	Instructor 1 lecture hour
Fall 2020, Spring 2021	PhD Student Seminar	3	Course Coordinator
Fall 2021, Spring 2022	Introduction to U.S. Health Care Policy, Undergraduate	30	Instructor 1 lecture hour
Fall 2020	Health Care Under the Trump Administration, Undergraduate	30	Instructor 1 lecture hour
Fall 2019	Universities Allied for Essential Medicines Panel Discussion, Undergraduate Organization	30	Panelist 1 lecture hour
Fall 2019	VUSM Medical Ethics, Law, and Policy Group	80	Instructor 1 lecture hour
Spring 2019, Spring 2020, Spring 2021, Spring 2022	PUBH 5512: Decision Analysis in Medicine and Public Health, elective course for Masters in Health Policy Concentration and PhD in Health Policy	15	3 lecture hours
Fall 2018, 2019, 2020, 2021	HODH 3231: Introduction to Health Services, Undergraduate elective	23	Instructor 1 lecture hour
Fall 2018, 2019, 2020, 2021	PUBH 5520: Introduction to Health Policy, 3 credit hours, required Masters in Health Policy Concentration	24	Instructor 2 lecture hours
Fall 2018	Nikpay Health Policy Course, 3 credit hours, Undergraduate elective	20	Instructor 1 lecture hour
Spring 2018, 2019, 2020, 2022	PUBH 5525: Health Economics, Economics of Prescription Drugs, 2 credit hours, required Masters in Health Policy Concentration and PhD in Health Policy	10	Instructor 2 lecture hours, 1 lab hour
Summer 2018	Grand Rounds: Vanderbilt University School of Medicine	100	Instructor 1 lecture hour

**UNC – Eshelman School of Pharmacy**

<b>Term</b>	<b>Course number, title, type</b>	<b>Enrollment</b>	<b>Responsibility</b>
Fall 2017	DPOP 899, Division Seminar	10	Instructor 3 lecture hours
Fall 2016	DPOP 804 / HPM804, Introduction to Healthcare Database Research, 3 credit hours, required Ph.D. course (DPOP), open elective	30	Course Director 24 lecture hours / 39 contact hours
Fall 2016	PHCY 609, The US Healthcare System, 2 credit hours, required PharmD course	165	Instructor 3 lecture hours
Fall 2016	DPOP 806: Pharmaceutical Policy, 3 credit required Ph.D. course and PharmD elective	15	Instructor 1 lecture hour
Spring 2015	DPOP 870, Pharmaceutical Outcomes Research, 3 credit required PhD course	15	Instructor 3 lecture hours
Fall 2014	DPOP 806: Pharmaceutical Policy, 3 credit required Ph.D. course and PharmD elective	15	Instructor 1 lecture hour
Spring 2013	DPOP 870, Pharmaceutical Outcomes Research, 3 credit required PhD course	20	Instructor 3 lecture hours

**UNC – Gillings School of Global Public Health**

Fall 2017	HPM 754 - Health Care in the United States: Structure and Policy, 3 credit hours, required residential and executive masters students	60	Instructor 1 lecture hour
Fall 2017	HPM 766 - Equity in Cancer Care Quality, 3 credit hours, PhD elective	15	Instructor 1 lecture hour
Fall 2017	EPID 771: Cancer Epidemiology Methods, 3 credit Ph.D. elective	20	Instructor 1 lecture hour
Fall 2017	HPM 873: First Year PhD Seminar, 3 credit required Ph.D. course	15	Instructor 1 lecture hour
Spring 2017	PUBH 701: Cost Effectiveness in Context, 3 credit elective course	25	Instructor 1 lecture hour
Fall 2016	HPM 754 - Health Care in the United States: Structure and Policy, 3 credit hours, required residential and executive masters students	60	Instructor 1 lecture hour
Fall 2016	HPM 766 - Equity in Cancer Care Quality, 3 credit hours, PhD elective	15	Instructor 1 lecture hour

Fall 2016	EPID 771: Cancer Epidemiology Methods, 3 credit Ph.D. elective	20	Instructor 1 lecture hour
Spring 2016	HPM 873: First Year PhD Seminar, 3 credit required Ph.D. course	15	Instructor 1 lecture hour
Spring 2016	PUBH 701: Cost Effectiveness in Context, 3 credit elective course	25	Instructor 1 lecture hour
Fall 2015	HPM 754 - Health Care in the United States: Structure and Policy, 3 credit hours, required residential and executive masters students	60	Instructor 1 lecture hour
Fall 2015	HPM 766 - Equity in Cancer Care Quality, 3 credit hours, PhD elective	15	Instructor 1 lecture hour
Fall 2015	EPID 771: Cancer Epidemiology Methods, 3 credit Ph.D. elective	20	Instructor 1 lecture hour
Spring 2015	HPM 873: First Year PhD Seminar, 3 credit required Ph.D. course	15	Instructor 1 lecture hour
Spring 2015	PUBH 701: Cost Effectiveness in Context, 3 credit elective course	25	Instructor 1 lecture hour
Spring 2015	EPID 766: Epidemiologic Research Using Healthcare Databases, 3 credit Ph.D. elective course	30	Instructor 4 lecture hours
Spring 2015	HPM 781: Comparative Effectiveness Research Methods, 3 credit Ph.D. elective course	15	Instructor 1 lecture hour
Fall 2014	HPM 754 - Health Care in the United States: Structure and Policy, 3 credit hours, required residential and executive masters students	60	Instructor 1 lecture hour
Spring 2014	HPM 873: First Year PhD Seminar, 3 credit required Ph.D. course	15	Instructor 1 lecture hour
Spring 2014	PUBH 701: Cost Effectiveness in Context, 3 credit elective course	25	Instructor 1 lecture hour
Spring 2014	EPID 893: Pharmacoepidemiology Seminar, 3 credit elective course	25	Instructor 1 lecture hour
Fall 2013	HPM 754 - Health Care in the United States: Structure and Policy, 3 credit hours, required residential and executive masters students	60	Instructor 1 lecture hour

Spring 2013	HPM 781: Comparative Effectiveness Research Methods, 3 credit Ph.D. elective course	15	Instructor 1 lecture hour
Spring 2013	HPM 873: First Year PhD Seminar, 3 credit required Ph.D. course	15	Instructor 1 lecture hour
<b>UNC – School of Medicine</b>			
Fall 2017	MD/PhD Program Research Seminar	50	Instructor 1 lecture hour
Spring 2017	GI Epi Conference, Seminar	30	Instructor 1 lecture hour
Spring 2017	Oncology Faculty Meeting	20	Guest Presentation 0.5 lecture hours
<b>UNC – Carolina Health Informatics Program</b>			
Fall 2017	INL 890, Health Informatics Seminar	20	Instructor 1 lecture hour

**Advising Activities****Vanderbilt University, PhD in Health Policy**

2020 – Present	<u>Nathaniel Tran</u> (Co-Advisor with Gilbert Gonzales)
2021 – Present	<u>Robert Besaw</u>
2022 – Present	<u>Khrysta Baig</u>

**Vanderbilt University, Masters Program in Medicine, Health & Society**

2018 – 2019      Lauren Taylor – Thesis: Evaluating Financial Burdens and Cost-Related Nonadherence in Patients with Chronic Blood Cancers

2019 – 2021      Alexandra Erath – Vanderbilt Medical School, Research Immersion Program

**UNC Eshelman School of Pharmacy Pharmaceutical Outcomes and Policy Ph.D. Program Advisor**

2015 – 2020      Matt Dixon – Thesis: Effect of Colorectal Cancer on Antidepressant Medication Utilization, and the Factors Associated with Discontinuation Among Medicare Patients  
Honors: Cancer Care Quality Post-Doctoral Fellowship, UNC  
Current Position: Associate Director for Worldwide Health Economics and Outcomes Research – Colorectal Cancer, BMS

2015 – 2018      Ashley Cole – Thesis: Comparative Safety and Healthcare Resource Utilization Associated with First-Line Treatments for Chronic Myeloid Leukemia.  
Honors: NRSA Pre-Doctoral Fellowship, Cecil G. Sheps Center for Health Services Research, UNC; American Foundation for Pharmaceutical Education (AFPE) Pre-Doctoral Fellowship in Pharmaceutical Sciences  
Current Position: Research Director at GSK

2015 – 2018      Nirosha Mahendraratnam Thesis: Optimizing Antiemetic Use to Prevent Chemotherapy Induced Nausea and Vomiting: Lessons Learned with Big Data and Modeling.  
Honors: Awarded BMS Pre-Doctoral Fellowship  
First Post-Graduate Position: United States Food and Drug Administration



Current Position: Director of Real-World Evidence Strategy, Aetion

- 2014 – 2018      Yi-Ting (Zoey) Chou – Thesis: Accessibility and Affordability of High Priced Drugs in Advanced Non-Small Cell Lung Cancer.  
Current Position: Post-doctoral fellow at UCSF
- 2014 – 2017      Robert Overman – Thesis: Prediction and Utility of a Clinical Fracture Risk Score in Administrative Claims.  
Current Position: Data Scientist, Novartis Inc.
- 2015 – 2017      Mrudula Borse – Thesis: Comparative Effectiveness and Safety of Anticoagulants in the Management of Venous Thromboembolism in Elective Major Orthopedic Surgery Patients.  
Current Position: Manager in the Health Economics & Market Access division of Ethicon, Inc.

**UNC Eshelman School of Pharmacy Pharmacotherapy and Experimental Therapeutics Ph.D. Dissertation Committee Member**

- 2016 – 2019      Olivia Dong – Thesis: Preemptive Pharmacogenomic Testing with DNA2RX™ in Cardiac Catheterization Laboratory Patients (Expected Completion, May 2018)  
Current Position: Post-Doctoral Research Fellow, Duke

**UNC Eshelman School of Pharmacy, PharmD Honors Program Advisor**

- 2015 – 2017      Steven Otto  
2015 – 2017      Hugh Heldenbrand

**Carolina Health Informatics Program (CHIP), Masters in Informatics**

- 2015 – 2017      Kathryn Morbitzer

**UNC School of Medicine**

- 2014 – 2017      Andrew B. Smitherman, MD and Research Fellow  
Division of Pediatrics and Hematology/Oncology, UNC School of Medicine  
Honors: Awarded St. Baldrick's Foundation fellowship  
**Role:** Primary Research Mentor  
Current Position: *Tenure Track Assistant Professor, University of North Carolina at Chapel Hill, School of Medicine, Pediatric Hematology / Oncology*
- 2015 – 2018      Aaron Mitchell, MD and Research Fellow  
Division of Hematology/Oncology, UNC School of Medicine  
Honors: Awarded a post-doctoral fellowship from the Cecil G. Sheps Center for Health Services Research  
**Role:** Research Co-Mentor with Ethan Basch (Hematology/Oncology)  
Honors: ASCO Merit Award, 2017; Conquer Cancer Foundation, Outstanding Fellow Award, North Carolina Oncology Association, Pope Clinical Trainee Award  
Current Position: *Assistant Professor, Memorial Sloan Kettering Cancer Center*

- 2017 – 2018      Laura Higginbotham, MD and Research Fellow  
 Chief Resident, Preventive Medicine, UNC School of Medicine  
Masters Thesis: Immunotherapy in Advanced Stage Melanoma: Patterns of Use and Effectiveness  
**Role**: Research Co-Mentor with Charles Poole (Epidemiology)  
Current Position: Physician, United States Food and Drug Administration, Office of New Drugs
- 2015 – 2017      Danielle Mohabir, MD/PhD Student  
 UNC School of Medicine and Department of Health Policy and Management  
**Role**: Summer Research Rotation Mentor

**Gillings School of Global Public Health, Department of Health Policy and Management Ph.D. Program Advisor**

- 2018 – 2021      Neela Kumar – Thesis: The Effects of High Deductible Health Plans on Adherence and Cost Sharing for Adults with Diabetes
- 2016 – 2021      Shelley Jazowski – Thesis: Association between Low-income Subsidies and Racial Disparities in Anticancer Treatment Use and Outcomes Among Medicare Beneficiaries with Multiple Myeloma.  
Honors: Pre-doctoral fellow, Duke Clinical Research Institute  
Current Position: *Post-doctoral research fellow, Vanderbilt University School of Medicine, Department of Health Policy*
- 2013 – 2017      Aaron Winn – Thesis: The Impact of Market Structure on Oncology Care.  
Honors: Royster Society of Fellows, 5 Year Merit Scholarship  
Current Position: *Tenure-Track Assistant Professor, Medical College of Wisconsin, School of Pharmacy*
- 2013 – 2016      Devon Check – Thesis: Assessing Racial Disparities in Quality of Chemotherapy-Induced Side Effect Management among Medicare Beneficiaries with Early Stage Breast Cancer.  
Honors: Health Care Delivery Post-Doctoral Fellow, Kaiser Northern California  
Honors: Jean G. Yeats Outstanding Doctoral Student Award  
First Post-Graduate Position: *Delivery Science Fellow at the Kaiser Permanente Northern California Division of Research*  
Current Position: *Assistant Professor, Duke University, Department of Population Health Sciences*

**Gillings School of Global Public Health, Department of Health Policy and Management Dr.Ph. Program Advisor**

- 2015 – 2018      David Nimke – Thesis: Do as I Say, Not as I Do: A cohort study of commercially insured families and the relationship between parental and child adherence and persistence with chronic medication.
- 2015 – 2019      Dana Wollins – Thesis: Integrating Doctor-Patient Cost Discussions into Oncology Practice. (Expected graduation May 2019)

**Gillings School of Global Public Health, Department of Health Policy and Management Ph.D. Dissertation Committee Member**

- 2018 – 2022      Wendi (Elkins) Rotunda – Thesis: Impact of High Costs for Oral Anticancer Drugs: Access, Death, and Net Worth  
Current Position: RTI, International
- 2017 – 2019      Natalie Ernecoff – Thesis: The Impact of Palliative Practices of Non-Specialty Palliative Care Providers on Utilization among Patients with Serious Illness  
Current Position: Instructor, University of Pittsburgh School of Medicine
- 2017 – 2019      Paul Shafer – Thesis: Effect of the Affordable Care Act on Utilization of Emergency and Primary Care.  
Current Position: Assistant Professor of Health Policy, Boston University
- 2017 – 2022      Hadi Beyhaghi - Thesis: Evidence-Based Prescribing of a Ipilimumab vs. Dacarbazine for Advanced Melanoma, Integrating treatment effectiveness and patient values.
- 2015 – 2018      Sam Savitz – Thesis: Health literacy in treatment selection & medication adherence: Application to stable angina.  
Current Position: *Delivery Science Fellow at the Kaiser Permanente Northern California Division of Research*
- 2014 – 2020      Lisa Selker – Thesis: Impact of Black Box Warnings on Drug Prescribing.
- 2013 – 2016      Megan Roberts – Thesis: Racial Variation in the Use of Oncotype Dx Testing Among Women with Breast Cancer.  
First Post-Graduate Position: *Post-doctoral trainee, NCI*  
Current Position: *Tenure-Track Assistant Professor, University of North Carolina at Chapel Hill, Eshelman School of Pharmacy*
- 2013 – 2016      Sarah Lewis – Thesis: Assessing Quality of Non-Cancer Chronic Care and Medication Adherence for Comorbidities among Prostate Cancer Survivors.  
Current Position: *Prevention Effectiveness Fellow, Office of the Assistant Secretary for Planning and Evaluation, Health Policy*
- 2014 – 2016      Regina Rutledge – Thesis: The Role of Provider, Site of Care and Contraceptive Type in Birth Spacing.  
Current Position: *Research Public Health Analyst at RTI International*
- 2014 – 2016      Todd Durham – Thesis: Can Novel Competing Risks Prediction Models Improve Population Health in Adults with Newly Diagnosed Atrial Fibrillation?  
Current Position: *Biostatistician and Decision Scientist, Novan, Inc.*

**Gillings School of Global Public Health, Epidemiology Ph.D. Dissertation Committee Member**

- 2014 – 2017      Greta Bushnell – Thesis: Pediatric Anxiety: Pharmacotherapy and Psychotherapy and Serious Adverse Outcomes.  
Honors: *F31 Dissertation Awardee NIMH, New Investigator Award, American Society of Clinical Psychopharmacology (2016)*

Current Position: *Post-Doctoral Fellow, Psychiatric Epidemiology Training program (T32) at Columbia University, Department of Epidemiology*

2014 – 2016      Nadya Belenky – Thesis: Effects of Medicare Part D Implementation on Medicaid-Medicare Dual Eligibles with HIV  
Current Position: *Post-Doctoral Fellow, Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill*

**Gillings School of Global Public Health, Department of Health Policy and Management MHA Advisor**

2017 – 2018      Kristen Leloudis – Thesis: Developing and Evaluating Novel Policy Solutions to Increase Access to Hepatitis C Medications for Incarcerated Patients

2016 – 2017      Carrie Blanchard

2016 – 2017      Wen Lin – Thesis: Comparisons of Value Frameworks for Oncology Drugs and Implications for Performance Based Pricing

**Gillings School of Global Public Health, Department of Health Policy and Management BSPH Advisor**

2016 – 2017      Victoria Hamby - Thesis: Understanding the Impact of Step Therapy Protocols on Physicians' Prescribing Decisions, Perceptions of Quality of Care, Autonomy, and Job Satisfaction within North Carolina

Honors: Graduated with Highest Honors; 2017 Arnold D. Kaluzny Award for Excellence in Undergraduate Research

Current Position: *Advisory Staff, EY*

**UNC School of Nursing Ph.D. Dissertation Committee Member**

2017 – 2019      Esita Patel – Thesis: Impact of State Level Nurse Practitioner Scope of Practice Regulation on Primary Care Diabetes Patient Utilization and Outcomes

Current Position: Post-doctoral Fellowship at Johns Hopkins School of Public Health

**Post-Doctoral Trainees**

Shelley A. Jazowski, PhD      June 2021 – Present  
Prior: PhD Program in Health Policy and Management, UNC Chapel Hill

Xuanzi (Shirley) Qin, PhD      December 2020 – July 2022  
Prior: PhD Program in Health Services, Policy, and Administration, University of Minnesota  
Accepted Position: Assistant Professor, University of Maryland

Shellie Ellis, PhD      2014  
Prior: PhD Program in Health Policy and Management, UNC Chapel Hill  
Current Position: *Associate Professor, with Tenure, University of Kansas School of Medicine*

**g) Grant Support – Active**

Leukemia & Lymphoma (Dusetzina; Nicholas) 06/01/2022 – 05/31/2024

Making the Right Choice: Medicare Plan Selection and Access to Cancer Care

The proposed project evaluates the financial and health outcomes for individuals selecting different Medicare coverage options and how these outcomes vary by the presence and timing of a cancer diagnosis. The goal of this work is to identify opportunities to improve plan selection and reduce inequities in cancer care and outcomes.

Role: PI

1R37CA264563-01A1 NCI (Mitchell) 7/01/2021 – 6/30/2026

Understanding the Importance of Industry Relationships for Cancer Care Quality, Outcomes, and Costs  
Conflict of interest (COI) between physicians and the drug industry is common, increasing, and influences medical practice. The short-term project goal is to evaluate the association between industry payments and cancer care quality, patient outcomes, and costs. The long-term research goal is to understand the importance of physician-industry financial relationships within the US healthcare system.

Role: Co-I

CMMI (RAND) 6/01/2021 – 9/30/2024

Part D Senior Savings Model Evaluation

This project will evaluate a change to the Medicare Coverage Gap Discount Program to allow participating Part D sponsors, through eligible enhanced alternative plans, to offer a Part D benefit design that includes predictable copays in the deductible, initial coverage, and coverage gap phases.

Role: Co-I

1R01AG068606-01 (Keohane) NIA 09/01/2020 - 06/30/2024

Diabetes, Dementia, and Aging at Home

The specific aims of this study are to: 1) Describe transitions into home-and-community-based services and nursing homes for older adults with diabetes and identify which factors, including dementia, limited social support, and insulin use, predict these transitions; 2) To evaluate whether more generous Medicaid home-and-community-based service coverage is associated with changes in days at home, inpatient and emergency room use, nursing home entry, and treatment for hypoglycemia; and 3) To assess whether beneficiaries with more generous Part D plan coverage or greater Part D subsidies are more likely to use simpler insulin options.

Role: Co-I

Commonwealth Fund (Dusetzina) 09/01/2020 - 08/30/2023

Evaluating the Role of Rebates on Medicare Formulary Coverage, Market Share, and Patient and Plan Spending. We will document drug list and net price trends in Medicare and examine the relationship between average rebate size and Part D formulary placement, beneficiary cost sharing, and product market share within a drug class. We will also assess trends in list and net prices for Part D drugs after generic competition occurs and whether drugs with large rebates have more generous formulary coverage and less use of generic alternatives. Finally, we will explore pricing dynamics and market share for authorized generics, including their use relative to traditional brands and traditional generics for the same product.

Role: PI

Laura and John Arnold Foundation (Dusetzina) 09/01/2020 - 08/30/2023  
Co-funding for project: Evaluating the Role of Rebates on Medicare Formulary Coverage, Market Share, and Patient and Plan Spending.  
Role: PI

VUMC/ (Sachs) Laura and John Arnold Foundation 07/01/2020 - 06/30/2023  
State Medicaid Programs and the FDA's Accelerated Approval Pathway  
Role: Site PI/Co-I

2P30CA068485 (Pietenpol) NCI, Cancer Center Support Gant 09/01/2020 - 08/31/2025  
Support for cancer health services research collaborations, including SEER-Medicare studies and other related health outcomes or policy work.  
Role: Staff Investigator

K23DE028010-01A1 (Smith) NIDCR 04/01/2019 – 03/31/2024  
Developing an oral health screening tool for an integrated model of care to reduce treatment-related oral morbidity in head and neck cancer survivors  
This study proposes to improve our understanding of barriers to care and statistical infrastructure needed to implement a novel oral care model to provide medical professionals and their support staff with a screening tool which would allow them to identify patients that are at high risk for oral disease.  
Role: Co-Mentor (Effort in Kind)

**Grant Support –Completed**

RWJF (Dusetzina/Everson) Robert Wood Johnson Foundation 03/01/2020-11/30/2022  
Using Drug Pricing Tools to Inform Cost Conversations  
In the proposed study we will 1) conduct community engagement focus groups with patients, prescribers and the clinical staff that currently have medication cost conversations; 2) implement surveys to test and extend key themes emerging from focus groups in larger samples; and 3) implement a vignette-based fractional factorial experiment to investigate how key implementation decisions, prescription characteristics, and patient demographics influence providers' decision making and confidence in engaging in a cost conversation.  
Role: Co-PI

VUMC74193 (PI: Conti, Site PI: Dusetzina) Leukemia and Lymphoma Society 6/1/2016 – 12/31/2022  
Project: Assessing the value of cancer therapies among patients and providers.  
In this study we will measure the level of financial burden and contributors to financial burden among patient with blood cancers. The goals are to determine the prevalence of financial burden in patients with multiple myeloma and chronic lymphocytic leukemia and to investigate mediators of financial burden for developing patient, provider, or site level interventions.  
Role: Site PI; Co-Investigator

NIHCM (Mitchell) 1/01/2021 – 12/31/2021  
Can Conflict of Interest with the Drug Industry Harm Patients?  
Conflict of interest (COI) between physicians and the drug industry is common, increasing, and influences medical practice. However, whether COI can induce physicians to deliver care that is harmful to patients is unknown. To address this question, we propose to assess whether physician COI is

associated with selection of less-beneficial cancer treatments (objective 1) or with delivery of low-value cancer interventions (objective 2).

Role: Co-I (Effort in Kind)

20181785 (Dusetzina) Commonwealth Fund 09/01/2018 - 08/31/2021

Identifying cost and coverage barriers to Medicare beneficiary access to specialty drugs

The goal of this study is to identify rates of treatment initiation among Medicare beneficiaries prescribed medications to treat cancer, HIV, Hepatitis C, rheumatoid arthritis, and multiple sclerosis. We will also evaluate the relationship between drug prices, insurance coverage, and adherence to prescribed medications.

Role: PI

VUMC69249(PHP9000-20) (Dusetzina) Leukemia & Lymphoma Society 09/01/2018 - 08/31/2021

Identifying cost and coverage barriers to Medicare beneficiary access to specialty drugs

The goal of this study is to identify rates of treatment initiation among Medicare beneficiaries prescribed medications to treat cancer, HIV, Hepatitis C, rheumatoid arthritis, and multiple sclerosis. We will also evaluate the relationship between drug prices, insurance coverage, and adherence to prescribed medications.

Role: PI

VUMC69760 (KFF / Dusetzina) The Laura and John Arnold Foundation 10/01/2018 - 09/30/2020

Generic Exclusion and Non-Preferred Placement in Medicare Part D in 2016 and Trends over Time. The goal of this study is to evaluate incentives to use higher versus lower priced drugs within the Medicare Part D program and to better understand the uptake and use of generic drugs among older adults.

Role: PI

Patient Centered Outcomes Research Institute (PCORI) (PI: Ron Chen) – 2/1/2016 – 2/01/2019

Project: Optimizing the effectiveness of routine post-treatment surveillance in prostate cancer survivors To understand risks and benefits of post-treatment surveillance strategies for men with prostate cancer.

Role: Co-Investigator, Lead Methodologist (25% Years 1-3) (\$1,161,162)

American Cancer Society (PI: Dusetzina) – 7/1/2014-6/30/2017

Research Scholar Grant (R01-equivalent)

Project: Impact of Oral Cancer Parity Legislation on Use and Costs of Cancer Care (\$479,932)

Role: Principal Investigator (20% Years 1-2, 15% NCE)

R34 1R34MH107588 (PI: Glickman) - 9/1/2015-08/30/2017

National Institute of Mental Health (NIMH)

Project: Novel Use of Mobile Integrated Emergency Medical Services to Improve Outcomes of Mental Health Emergencies (\$400,399)

Role: Co-Investigator (Effort in-kind year 1, 20% Year 2)

Carolina's Collaborative Pilot Grant (PI: Willis) - 9/1/2017-8/30/2018

Project: Antibiotic prescribing in NC before and after an FDA boxed warning on fluoroquinolones in 2016

Role: Co-Investigator (Effort in Kind) (\$50,000)

550KR131607 (PI: Dusetzina) - 7/1/2016-6/30/2017

NC TraCS CER Program:

Project: Less is More? Evaluating Surveillance Patterns after Non-Operative Management Compared to Conventional Management for Older Individuals with Rectal Cancer (\$50,000)

Data@Carolina Course Development Grant Program (PI: Dusetzina) – 4/28/2016 – 8/01/2016  
Project: Development of DPOP 804/HPM 804 course materials (\$9,449).  
Role: Course Director / Developer

550KR101503 (PI: Chen) - 5/1/2015-4/30/2016  
NC TraCS CER Program  
Project: Aggressive End-of-Life Care among Patients with Cancer under Age 65: Analysis of the HealthCore Integrated Research Database (\$50,000)  
Role: Co-Investigator (In Kind, Year 1)

CERR11402 (PI: Reeder-Hayes) – 1/1/2015-12/31/2015  
NC TraCS CER Program  
Project: Comparative Effectiveness of Trastuzumab-Based Chemotherapy Regimens for Early Stage Breast Cancer (\$50,000)  
Role: Co-Investigator (In Kind, Year 1)

NIH Building Interdisciplinary Research Careers in Women's Health (BIRCWH) K12 Program  
(PI: Dusetzina; KL2 PI: Orringer / Boggess) - 07/01/2013–06/30/2016  
Role: Scholar (75% Years 1-3)  
Project: Treating the whole patient: evaluating the use of depression treatments during the year following a new colorectal or breast cancer diagnosis.

HSA2902010000141 (PI: M. Alan Brookhart) – 9/1/2012-8/31/2014  
Role: Co-Investigator (20% Year 1; 15% Year 2)  
AHRQ DEcIDE Program. Developing and Evaluating Methods for Record Linkage and Reducing Bias in Patient Registries (\$1,112,042)

R01HS018960 (PI: G. Caleb Alexander) – 7/1/2010-6/30/2014  
Role: Consultant (Effort in Kind Years 1-2; 15% Effort Years 3-4)  
Assessing the Effect of FDA Advisories on Provider, Patient, and Firm Behavior

T32MH019733-17 (PI: Richard Frank / Haiden Huskamp) – 7/1/10-6/30/12  
Role: Research Fellow / Trainee  
National Institutes of Mental Health National Research Service Award (NRSA) Post-Doctoral Traineeship in Mental Health Services Research at the Department of Health Care Policy, Harvard Medical School.

T32HS000032-20 (PI: Timothy Carey) – 9/1/08-6/30/10  
Agency for Healthcare Research and Quality (AHRQ) National Research Service Award (NRSA) T-32 Pre-doctoral Traineeship at the Cecil G. Sheps Center for Health Services Research, UNC-CH.



**Honors and Awards**

Vanderbilt-Ingram Cancer Center 2021 Star Award	2021
VUMC Biomedical Science Impact Award (X1)	2021
VUMC Biomedical Science Impact Award (X2)	2020
Vanderbilt-Ingram Cancer Center 2019 Star Award	2020
VUMC Biomedical Science Impact Award (X2)	2019
National Academy of Medicine Emerging Leader	2019
Becker's Rising Stars – 66 Leaders in Healthcare Under 40	2019
Expert Witness for Senate Aging Committee Hearing on The Complex Web of Prescription Drug Prices: <a href="https://www.aging.senate.gov/hearings/the-complex-web-of-prescription-drug-prices-part-ii-untangling-the-web-and-paths-forward">https://www.aging.senate.gov/hearings/the-complex-web-of-prescription-drug-prices-part-ii-untangling-the-web-and-paths-forward</a>	2019
National Academies of Sciences, Engineering and Medicine Committee Member Study: Ensuring Patient Access to Affordable Drugs <a href="http://www8.nationalacademies.org/cp/CommitteeView.aspx?key=49817">http://www8.nationalacademies.org/cp/CommitteeView.aspx?key=49817</a>	2016, 2017
Invited Participant, President's Cancer Panel Workshop <a href="http://www.aspph.org/unc-faculty-member-invited-to-inform-presidents-cancer-panel-about-cancer-drug-pricing-and-access/">http://www.aspph.org/unc-faculty-member-invited-to-inform-presidents-cancer-panel-about-cancer-drug-pricing-and-access/</a>	2016, 2017
NRSA Post-Doctoral Fellowship in Mental Health Services Research	2010 - 2012
NRSA Pre-Doctoral Fellowship - Cecil G. Sheps Center for Health Services Research	2008 - 2010
Kathryne A. Brewington Graduate Research Award	2009
APhA-APRS ESAS Postgraduate Best Paper Podium Award (Finalist)	2009
Rho Chi Honor Society – UNC Eshelman School of Pharmacy	2008
Eshelman Fellowship – UNC Eshelman School of Pharmacy	2007
Golden Key Honor Society – UNC Chapel Hill	2007
Highest Quality Achievement Award – Rho, Inc.	2005
Reaching Above and Beyond Award – Rho, Inc.	2004

**h) Professional Service**

Commissioner, Medicare Payment Advisory Commission, May 2021 - Present  
Faculty Advisory Council Member, Vanderbilt University School of Medicine, December 2020 - Present  
Research Council Member, Tradeoffs Podcast, January 2021 - Present  
E2PS Research Director, Vanderbilt University School of Medicine, June 2020 - Present  
Invited participant, Listening Session with Seema Verma on Paying for Cures, July 2019  
Special Expert, Health Economist Representative for the National Cancer Institute's Cancer Care Delivery Research Steering Committee, August 2018 - Present  
Advisory Board Member, AHRQ NRSA Fellowship Program, UNC Chapel Hill, August 2018 - Present  
NCI PDQ Adult Treatment Editorial Board – Financial Toxicity & Cancer, March 2018 - Present  
ICER Midwest Comparative Effectiveness Public Advisory Council Member, March 2018 - Present  
Panelist, Assessing the Public Health Impact of Prescription Drug Postmarket Safety Labeling Changes, Duke-Margolis Center for Health Policy, Washington DC, February 2018  
Penn LDI Gene and Cell Therapy Symposium, Advisory Committee Member, January – September 2018  
ASCO Organizing Committee Member, Pre-Conference Session on Cancer Economics, July 2017 - Present  
Reviewer, Eshelman Institute for Innovation Student Pitch Day, November 2016  
Graduate Program Visionary Committee, UNC Eshelman School of Pharmacy, April 2017 - Present  
ASCO Health Services Research Oral Session Discussant, June 2016  
Ad-Hoc Grant Reviewer, American Cancer Society  
ASCO Antiemetics Guideline Panel Member  
Admissions Committee, UNC Eshelman School of Pharmacy, Division Representative, 2014-2017

Appointment, Reappointment, Promotion & Tenure Committee, UNC Eshelman School of Pharmacy  
 Taking Action by Service (TABS) Faculty Mentor, UNC Eshelman School of Pharmacy PharmD Program  
 Steering Committee Member – Integrated Cancer Information and Surveillance System (ICISS)

### **Invited Presentations**

Harvard Medical School	January 2023
Center for Drug Safety and Effectiveness, Johns Hopkins	January 2023
AcademyHealth Organizational Member Briefing, Topics in Health	October 2022
Breastcancer.org – Financial Toxicity of Breast Cancer	October 2022
IQVIA Institute for Human Data Science	October 2022
Stanford Health Policy, Advancing Health Equity Symposium	October 2022
National MS Society, What Does the New Drug Pricing Law Mean for You	August 2022
STAT - Democrats' Last Chance for Drug Pricing Reform	July 2022
IQVIA Institute for Human Data Science	May 2022
Yale School of Medicine	May 2022
Office of Health Economics 60 <sup>th</sup> Anniversary Event	April 2022
POLITICO Health Care Summit	March 2022
University of California, San Francisco	November 2021
Stanford University	November 2021
National Academy of Medicine, Promoting Health Equity in Cancer	October 2021
Charles C. Leighton, MD Memorial Lecture, University of Pennsylvania	April 2021
University of Washington	April 2021
Auburn University Harrison School of Pharmacy	February 2021
National Institutes of Health Joint Bioethics Colloquium	April 2020
National Academy of Medicine, Implications of Discarded Weight-Based Drugs	April 2020
Harvard Medical School Center for Bioethics	September 2019
Medical Grand Grounds, Oregon Health & Science University	June 2019
Center for Drug Safety and Effectiveness, Johns Hopkins	April 2019
Division of Health Policy and Insurance Research, Harvard Medical School	March 2019
Center for Pharmaceutical Policy and Prescribing, University of Pittsburgh	December 2018
Panelist, Brookings Institution, A Conversation with Seema Verma	October 2018
Center for Health Incentives & Behavioral Economics, Penn	September 2017
Fred Hutchison Cancer Center	July 2017
Duke Medical School, Department of Population Health Sciences	June 2017
American Society of Clinical Oncology, Economics of Cancer Care	June 2017
Vanderbilt School of Medicine	April 2017
University of Chicago, School of Medicine	December 2015
Dana Farber Cancer Institute	November 2015
Board of Trustees Meeting, UNC Chapel Hill	July 2015
Harvard Medical School, Department of Population Medicine	April 2015
Memorial Sloan Kettering Cancer Center	December 2014
Board of Visitors Meeting, UNC Eshelman School of Pharmacy	December 2014
Board of Visitors Meeting, UNC Lineberger Comprehensive Cancer Center	September 2014
Agency for Healthcare Research and Quality, Agency Meeting	July 2014
Center for Health Services Research in Primary Care, Durham Veterans Affairs	December 2013
University of Pennsylvania, Center for Clinical Epidemiology and Biostatistics	March 2012
Perelman School of Medicine	
UNC, NC Translational and Clinical Sciences Institute	March 2012

**Professional Association Membership and Service**

AcademyHealth  
American Society of Health Economists  
International Society for Pharmacoepidemiology  
Abstract Reviewer – International Society for Pharmacoepidemiology  
Abstract Reviewer – Society for Medical Decision Making

**Editorial Activities – Editorial Board Member**

American Journal of Managed Care	September 2021 - Present
Journal of Health Politics Policy and Law - Special Issue Co-Editor	July 2021 - Present
JAMA Internal Medicine	March 2020 - Present
Journal of the National Cancer Institute	November 2017 - Present
Journal of Clinical Oncology – Special Series Co-Editor	November 2018 - Present

**Editorial Activities – Journal Reviewer (Selected)**

Annals of Internal Medicine	Cancer
Health Affairs	Health Services Research
Journal of the American Medical Association	JAMA Internal Medicine
Journal of Clinical Oncology	Journal of the National Cancer Institute
New England Journal of Medicine	Proceedings of the National Academy of Sciences

Awarded “Exceptional Reviewer” – Annals of Internal Medicine (2020)  
Highest-Quality Peer Reviews - Journal of Managed Care + Specialty Pharmacy (2020)  
Awarded “Top Peer Reviewer” – JNCI Cancer Spectrum (2018)  
Awarded “Best Reviewer” – Pharmacoepidemiology and Drug Safety (2013-2016)